ALPHA-CONOTOXIN PEPTIDES

Abstract
The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
Description
BACKGROUND OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.


The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference, and for convenience are referenced in the following text by author and date and are listed alphabetically by author in the appended bibliography.


The predatory cone snails (Conus) have developed a unique biological strategy. Their venom contains relatively small peptides that are targeted to various neuromuscular receptors and may be equivalent in their pharmacological diversity to the alkaloids of plants or secondary metabolites of microorganisms. Many of these peptides are among the smallest nucleic acid-encoded translation products having defined conformations, and as such, they are somewhat unusual. Peptides in this size range normally equilibrate among many conformations. Proteins having a fixed conformation are generally much larger.


The cone snails that produce these peptides are a large genus of venomous gastropods comprising approximately 500 species. All cone snail species are predators that inject venom to capture prey, and the spectrum of animals that the genus as a whole can envenomate is broad. A wide variety of hunting strategies are used; however, every Conus species uses fundamentally the same basic pattern of envenomation.


Several peptides isolated from Conus venoms have been characterized. These include the α-, μ- and ω-conotoxins which target nicotinic acetylcholine receptors, muscle sodium channels, and neuronal calcium channels, respectively (Olivera et al., 1985). Conopressins, which are vasopressin analogs, have also been identified (Cruz et al. 1987). In addition, peptides named conotoxins have been isolated from Conus geographus and Conus tulipa (Mena et al., 1990; Haack et al., 1990).


The α-conotoxins are small peptides highly specific for neuromuscular junction nicotinic acetylcholine receptors (Gray et al., 1981; Marshall and Harvey, 1990; Blount et al., 1992; Jacobsen et al., 1997) or highly specific for neuronal nicotinic acetylcholine receptors (Fainzilber et al., 1994; Johnson et al., 1995; Cartier et al., 1996; Luo et al., 1998). The α-conotoxins with specificity for neuromuscular junction nicotinic acetylcholine receptors are used as neuromuscular blocking agents for use in conjunction with surgery, as disclosed in U.S. patent application Ser. No. 09/488,799, filed 21 Jan. 2000, incorporated by reference herein. Additional α-conotoxins and uses for them have been described in U.S. Pat. Nos. 4,447,356 (Olivera et al., 1984); 5,432,155; 5,514,774, each incorporated herein by reference.


Additional uses for α-conotoxins are described in U.S. Ser. No. 09/219,446, filed 22 Dec. 1998, incorporated herein by reference. In this application, α-conotoxins with specificity for neuronal nicotinic acetylcholine receptors are used for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma.


It is desired to provide additional α-conotoxin peptides having uses as described herein.


SUMMARY OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.


More specifically, the present invention is directed to α-conotoxin peptides having the general formula I:


Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Cys-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Cys-Xaa10-Xaa11-Xaa12-Cys-Xaa13 (SEQ ID NO1:), wherein Xaa1 is des-Xaa1, Ile, Leu or Val; Xaa2 is des-Xaa2, Ala or Gly; Xaa3 is des-Xaa3, Gly, Trp (D or L), neo-Trp, halo-Trp or any unnatural aromatic amino acid; Xaa4 is des-Xaa4, Asp, Phe, Gly, Ala, Glu, γ-carboxy-Glu (Gla) or any unnatural aromatic amino acid; Xaa5 is Glu, Gla, Asp, Ala, Thr, Ser, Gly, Ile, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa6 is Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa7 is Asp, Glu, Gla, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa8 is Ser, Thr, Asn, Ala, Gly, Arg, Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, His, halo-His, Pro or hydroxy-Pro; Xaa9 is Thr, Ser, Ala, Asp, Asn, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa10 is Gly, Ser, Thr, Ala, Asn, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa11 is Gln, Leu, His, halo-His, Trp (D or L), halo-Trp, neo-Trp, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid or any unnatural aromatic amino acid; Xaa12 is Asn, His, halo-His, Ile, Leu, Val, Gln, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa13 is des-Xaa13, Val, Ile, Leu, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid. The C-terminus may contain a free carboxyl group or an amide group. The halo is chlorine, bromine or iodine, preferably iodine for Tyr and His and preferably bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to α-conotoxin peptides having the general formula II:


Xaa1-Xaa2-Xaa3-Xaa4-Cys-Cys-Xaa5-Xaa6-Xaa7-Xaa8-Cys-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Cys-Xaa15-Xaa16-Xaa17 (SEQ ID NO:2), wherein Xaa1 is des-Xaa1, Asp, Glu or γ-carboxy-Glu (Gla); Xaa2 is des-Xaa2, Gln, Ala, Asp, Glu, Gla; Xaa3 is des-Xaa3, Gly, Ala, Asp, Glu, Gla, Pro or hydroxy-Pro; Xaa4 is des-Xaa4, Gly, Glu, Gla, Gln, Asp, Asn, Pro or hydroxy-Pro; Xaa5 is Ser, Thr, Gly, Glu, Gla, Asn, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa6 is Asp, Asn, His, halo-His, Thr, Ser, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa7 is Pro or hydroxy-Pro; Xaa8 is Ala, Ser, Thr, Asp, Val, Ile, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa9 is Gly, Ile, Leu, Val, Ala, Thr, Ser, Pro, hydroxy-Pro, Phe, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid or any unnatural aromatic amino acid; Xaa10 is Ala, Asn, Phe, Pro, hydroxy-Pro, Glu, Gla, Gln, His, halo-His, Val, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa11 is Thr, Ser, His, halo-His, Leu, Ile, Val, Asn, Met, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa12 is Asn, Pro, hydroxy-Pro, Gln, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa13 is des-Xaa13, Gly, Thr, Ser, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa14 is des-Xaa14, Ile, Val, Asp, Leu, Phe, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; and Xaa15 is des-Xaa15, Gly, Ala, Met, Ser, Thr, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa16 is des-Xaa16, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa17 is des-Xaa17, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid. The C-terminus may contain a free carboxyl group or an amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for His or Tyr and bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to α-conotoxin peptides having the general formula III:


Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Cys-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Cys-Xaa10-Xaa-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Cys-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24 (SEQ ID NO:3), wherein Xaa1 is des-Xaa1, Ser or Thr; Xaa2 is des-Xaa2, Asp, Glu, γ-carboxy-Glu (Gla), Asn, Ser or Thr; Xaa3 is des-Xaa3, Ala, Gly, Asn, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa4 is des-Xaa4, Ala, Val, Leu, Ile, Gly, Glu, Gla, Gln, Asp, Asn, Phe, Pro, hydroxy-Pro or any unnatural aromatic amino acid; Xaa5 is des-Xaa5, Thr, Ser, Asp, Glu, Gla, Gln, Gly, Val, Asp, Asn, Ala, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa6 is Thr, Ser, Asp, Asn, Met, Val, Ala, Gly, Leu, Ile, Phe, any unnatural aromatic amino acid, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa7 is Ile, Leu, Val, Ser, Thr, Gln, Asn, Asp, Arg, His, halo-His, Phe, any unnatural aromatic amino acid, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa8 is Pro, hydroxy-Pro, Ser, Thr, Ile, Asp, Leu, Val, Gly, Ala, Phe, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa9 is Val, Ala, Gly, Ile, Leu, Asp, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa10 is His, halo-His, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Asn, Ala, Ser, Thr, Phe, Ile, Leu, Gly, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa11 is Leu, Gln, Val, Ile, Gly, Met, Ala, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Ser, Thr, Arg, homoarginine, ornithine, any unnatural basic amino acid, Asn, Glu, Gla, Gln, Phe, Trp (D or L), neo-Trp, halo-Trp or any unnatural aromatic amino acid; Xaa12 is Glu, Gla, Gln, Asn, Asp, Pro, hydroxy-Pro, Ser, Gly, Thr, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Arg, homoarginine, ornithine, any unnatural basic amino acid, Phe, His, halo-His, any unnatural aromatic amino acid, Leu, Met, Gly, Ala, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa13 is His, halo-His, Asn, Thr, Ser, Ile, Val, Leu, Phe, any unnatural aromatic amino acid, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Try, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa14 is Ser, Thr, Ala, Gln, Pro, hydroxy-Pro, Gly, Ile, Leu, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa15 is Asn, Glu, Gla, Asp, Gly, His, halo-His, Ala, Leu, Gln, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa16 is Met, Ile, Thr, Ser, Val, Leu, Pro, hydroxy-Pro, Phe, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, any unnatural hydroxy containing amino acid, Glu, Gla, Ala, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa17 is des-Xaa17, Gly, Asp, Asn, Ala, Ile, Leu, Ser, Thr, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa18 is des-Xaa18, Gly, Glu, Gla, Gln, Trp (D or L), neo, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa19 is des-Xaa19, Ser, Thr, Val, Ile, Ala, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa20 is des-Xaa20, Val, Asp, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa21 is des-Xaa21, Asn, Pro or hydroxy-Pro; Xaa22 is des-Xaa22, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa23 is des-Xaa23, Ser or Thr; Xaa24 is des-Xaa24, Leu, Ile or Val; with the proviso that (a) Xaa5 is not Gly, when Xaa1 is des-Xaa1, Xaa2 is des-Xaa2, Xaa3 is des-Xaa3, Xaa4 is des-Xaa4, Xaa6 is Ser, Xaa7 is His, Xaa8 is Pro, Xaa9 is Ala, Xaa10 is Ser, Xaa11 is Val, Xaa12 is Asn, Xaa13 is Asn, Xaa14 is Pro, Xaa15 is Asp, Xaa16 is Ile, Xaa17 is des-Xaa17, Xaa18 is des-Xaa18, Xaa19 is des-Xaa19, Xaa20 is des-Xaa20, Xaa21 is des-Xaa21, Xaa22 is des-Xaa22, Xaa23 is des-Xaa23, and Xaa24 is des-Xaa24. The C-terminus may contain a free carboxyl group or an amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for His and Tyr and bromine for Trp. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


The present invention is also directed to novel specific α-conotoxin peptides of general formula I having the formulas:

(SEQ ID NO:4)Asp-Xaa1-Cys-Cys-Ser-Asp-Ser-Arg-Cys-Gly-Xaa2-Asn-Cys-Leu;(SEQ ID NO:5)Ala-Cys-Cys-Ser-Asp-Arg-Arg-Cys-Arg-Xaa3-Arg-Cys;(SEQ ID NO:6)Phe-Thr-Cys-Cys-Arg-Arg-Gly-Thr-Cys-Ser-Gln-His-Cys;(SEQ ID NO:7)Asp-Xaa4-Cys-Cys-Arg-Arg-His-Ala-Cys-Thr-Leu-Ile-Cys;(SEQ ID NO:8)Asp-Xaa4-Cys-Cys-Arg-Xaa5-Xaa5-Cys-Thr-Leu-Ile-Cys;(SEQ ID NO:9)Gly-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Arg-Xaa4-Arg-Cys-Arg;(SEQ ID NO:10)Gly-Gly-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Ala-Xaa3-Arg-Cys;(SEQ ID NO:11)Ile-Ala-Xaa3-Asp-Ile-Cys-Cys-Ser-Xaa1-Xaa5-Asp-Cys-Asn-His-Xaa2-Cys-Val;and(SEQ ID NO:12)Gly-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Xaa2-His-Gln-Cys,


wherein Xaa1 is Glu or γ-carboxy-Glu (Gla); Xaa2 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa3 is Trp (D or L), halo-Trp or neo-Trp; Xaa4 is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa5 is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to the following α-conotoxin peptides of general formula I:

    • Im1.1: SEQ ID NO:4, wherein Xaa1 is Glu and Xaa2 is Lys;
    • Im1.2: SEQ ID NO:5, wherein Xaa3 is Trp;
    • Rg1.2: SEQ ID NO:6;
    • Rg1.6: SEQ ID NO:7, wherein Xaa4 is Tyr;
    • Rg1.6A: SEQ ID NO:8, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Rg1.7: SEQ ID NO:9, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Rg1.9: SEQ ID NO:10, wherein Xaa3 is Trp and Xaa5 is Pro;
    • Rg1.10: SEQ ID NO:11, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp and Xaa5 is Pro; and
    • Rg1.11: SEQ ID NO:12, wherein Xaa2 is Lys and Xaa5 is Pro.


      The C-terminus of Im1.1, Rg1.7 an Rg1.10 preferably contains a free carboxyl group. The C-terminus of Im1.2, Rg1.2, Rg1.6, Rg1.6A, Rg1.9 and Rg1.11 preferably contains an amide group.


The present invention is further directed to novel specific α-conotoxin peptides of general formula II having the formulas:

(SEQ ID NO:13)Cys-Cys-Ser-Asp-Xaa5-Ala-Cys-Xaa2-Gln-Thr-Xaa5-Gly-Cys-Arg;(SEQ ID NO:14)Cys-Cys-Xaa1-Asn-Xaa5-Ala-Cys-Arg-His-Thr-Gln-Gly-Cys;(SEQ ID NO:15)Gly-Cys-Cys-Xaa3-His-Xaa5-Ala-Cys-Gly-Arg-His-Xaa4-Cys;(SEQ ID NO:16)Ala-Xaa5-Cys-Cys-Asn-Asn-Xaa5-Ala-Cys-Val-Xaa2-His-Arg-Cys;(SEQ ID NO:17)Ala-Xaa5-Gly-Cys-Cys-Asn-Asn-Xaa5-Ala-Cys-Val-Xaa2-His-Arg-Cys;(SEQ ID NO:18)Xaa5-Xaa5-Cys-Cys-Asn-Asn-Xaa5-Ala-Cys-Val-Xaa2-His-Arg-Cys;(SEQ ID NO:19)Asp-Xaa1-Asn-Cys-Cys-Xaa3-Asn-Xaa5-Ser-Cys-Xaa5-Arg-Xaa5-Arg-Cys-Thr;(SEQ ID NO:20)Gly-Cys-Cys-Ser-Thr-Xaa5-Xaa5-Cys-Ala-Val-Leu-Xaa4-Cys;(SEQ ID NO:21)Gly-Cys-Cys-Gly-Asn-Xaa5-Asp-Cys-Thr-Ser-His-Ser-Cys;(SEQ ID NO:42)Gly-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Ala-His-Asn-Asn-Xaa5-Asp-Cys-Arg;(SEQ ID NO:154)Gly-Cys-Cys-Xaa4-Asn-Xaa5-Val-Cys-Xaa2-Xaa2-Xaa4-Xaa4-Cys-Xaa3-Xaa2;(SEQ ID NO:155)Xaa6-Xaa1-Xaa5-Gly-Cys-Cys-Arg-His-Xaa5-Ala-Cys-Gly-Xaa2-Asn-Arg-Cys;(SEQ ID NO:156)Cys-Cys-Ala-Asp-Xaa5-Asp-Cys-Arg-Phe-Arg-Xaa5-Gly-Cys;(SEQ ID NO:157)Gly-Cys-Cys-Xaa4-Asn-Xaa5-Ser-Cys-Xaa3-Xaa5-Xaa2-Thr-Xaa4-Cys-Ser-Xaa3-Xaa2;(SEQ ID NO:158)Cys-Cys-Ser-Asn-Xaa5-Thr-Cys-Xaa2-Xaa1-Thr-Xaa4-Gly-Cys;(SEQ ID NO:159)Cys-Cys-Ala-Asn-Xaa5-Ile-Cys-Xaa2-Asn-Thr-Xaa5-Gly-Cys;(SEQ ID NO:160)Cys-Cys-Asn-Asn-Xaa5-Thr-Cys-Xaa2-Xaa1-Thr-Xaa4-Gly-Cys;(SEQ ID NO:161)Cys-Cys-Ser-Asn-Xaa5-Val-Cys-Xaa2-Xaa1-Thr-Xaa4-Gly-Cys;(SEQ ID NO:162)Gly-Gly-Cys-Cys-Ser-Xaa4-Xaa5-Xaa5-Cys-Ile-Ala-Ser-Asn-Xaa5-Xaa2-Cys-Gly;(SEQ ID NO:163)Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Ser-Ala-Met-Ser-Xaa5-Ile-Cys;(SEQ ID NO:164)Gly-Cys-Cys-Xaa2-Asn-Xaa5-Xaa4-Cys-Gly-Ala-Ser-Xaa2-Thr-Xaa4-Cys;(SEQ ID NO:165)Gly-Cys-Cys-Ser-Xaa4-Xaa5-Xaa5-Cys-Phe-Ala-Thr-Asn-Xaa5-Asp-Cys;(SEQ ID NO:166)Gly-Gly-Cys-Cys-Ser-Xaa4-Xaa5-Xaa5-Cys-Ile-Ala-Asn-Asn-Xaa5-Leu-Cys-Ala;(SEQ ID NO:167)Gly-Gly-Cys-Cys-Ser-Xaa4-Xaa5-Xaa5-Cys-Ile-Ala-Asn-Asn-Xaa5-Phe-Cys-Ala;(SEQ ID NO:168)Asp-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Ser-Gln-Asn-Asn-Xaa5-Asp-Cys-Met;and(SEQ ID NO:169)Asp-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Ala-His-Asn-Asn-Xaa5-Asp-Cys-Arg,


wherein Xaa1 is Glu or γ-carboxy-Glu (Gla); Xaa2 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa3 is Trp (D or L), halo-Trp or neo-Trp; Xaa4 is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa5 is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to the following α-conotoxin peptides of general formula II:

    • Sn1.1: SEQ ID NO:13, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Sn1.2: SEQ ID NO:14, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Sl1.3: SEQ ID NO:15, wherein Xaa3 is Trp, Xaa4 is Tyr and Xaa5 is Pro;
    • A1.2: SEQ ID NO:16, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Bu1.1: SEQ ID NO:17, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Bu1.2: SEQ ID NO:18, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Bu1.3: SEQ ID NO:19, wherein Xaa1 is Glu, Xaa3 is Trp and Xaa5 is Pro;
    • Bu1.4: SEQ ID NO:20, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Cr1.3: SEQ ID NO:21, wherein Xaa5 is Pro;
    • Di1.1: SEQ ID NO:42 wherein Xaa5 is Pro;
    • Ms1.7: SEQ ID NO:154, wherein Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Tyr and Xaa5 is Pro;
    • P1.7: SEQ ID NO:155, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa5 is Pro and Xaa6 is Gln;
    • Ms1.2: SEQ ID NO:156, wherein Xaa5 is Pro;
    • Ms1.3: SEQ ID NO:157, wherein Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Tyr and Xaa5 is Pro;
    • Ms1.4: SEQ ID NO:158, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Ms1.5: SEQ ID NO:159, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Ms1.8: SEQ ID NO:160, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Ms1.9: SEQ ID NO:161, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Bt1.7: SEQ ID NO:162, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Lv1.5: SEQ ID NO:163, wherein Xaa5 is Pro;
    • Ms1.10: SEQ ID NO:164, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Om1.1: SEQ ID NO:165, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • R1.6: SEQ ID NO:166, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • R1.7: SEQ ID NO:167, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Vr1.1: SEQ ID NO:168, wherein Xaa5 is Pro; and
    • Vr1.2: SEQ ID NO:169, wherein Xaa5 is Pro.


      The C-terminus preferably contains a carboxyl group for the peptides 5 n1.1, 5 n1.2, Cr1.3, Di1.1, Ms1.2, Ms1.4, Ms1.5, Ms1.8, Ms1.9, Vr1.1 and Vr1.2. The C-terminus of the other peptides preferably contains an amide group.


The present invention is also directed to novel specific α-conotoxin peptides of general formula III having the formulas:

(SEQ ID NO:22)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-His-Leu-Xaa1-His-Ser-Asn-Met-Cys;(SEQ ID NO:23)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-Arg-Gln-Asn-Asn-Ala-Xaa1-Xaa4-Cys-Arg;(SEQ ID NO:24)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:25)Xaa5-Xaa1-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:26)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Asp;(SEQ ID NO:27)Xaa5-Arg-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:28)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Gly-Ile-Cys-Arg;(SEQ ID NO:29)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Thr-Cys-Arg;(SEQ ID NO:30)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Val-Cys-Arg;(SEQ ID NO:31)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Ile-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:32)Xaa5-Gln-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg-Arg-Arg-Arg;(SEQ ID NO:33)Gly-Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ala-Val-Asn-His-Xaa5-Xaa1-Leu-Cys;(SEQ ID NO:34)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Val-Asn-His-Xaa5-Xaa1-Leu-Cys;(SEQ ID NO:35)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys;(SEQ ID NO:36)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Gly-Xaa2-Thr-Gln-Xaa1-Xaa5-Cys-Arg-Xaa1-Ser;(SEQ ID NO:37)Xaa5-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Gly-Asn-Asn-Xaa5-Xaa1-Phe-Cys-Arg-Gln;(SEQ ID NO:38)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Gly-Asn-Asn-Xaa5-Xaa1-Phe-Cys-Arg-Gln;(SEQ ID NO:39)Gly-Cys-Cys-Ser-His-Xaa5-Xaa5-Cys-Ala-Met-Asn-Asn-Xaa5-Asp-Xaa4-Cys;(SEQ ID NO:40)Gly-Cys-Cys-Ser-His-Xaa5-Xaa5-Cys-Phe-Leu-Asn-Asn-Xaa5-Asp-Xaa4-Cys;(SEQ ID NO:41)Gly-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Ile-Ala-Xaa2-Asn-Xaa5-His-Met-Cys-Gly;(SEQ ID NO:43)Gly-Cys-Cys-Ser-Asn-Xaa5-Ala-Cys-Ala-Gly-Asn-Asn-Xaa5-His-Val-Cys-Arg-Gln;(SEQ ID NO:44)Gly-Cys-Cys-Ser-Arg-Xaa5-Ala-Cys-Ile-Ala-Asn-Asn-Xaa5-Asp-Leu-Cys;(SEQ ID NO:45)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-His-Val-Xaa1-His-Xaa5-Xaa1-Leu-Cys-Arg-Arg-Arg-Arg;(SEQ ID NO:46)Gly-Gly-Cys-Cys-Ser-Phe-Xaa5-Ala-Cys-Arg-Xaa2-Xaa5-Arg-Xaa5-Xaa1-Met-Cys-Gly;(SEQ ID NO:47)Xaa5-Xaa1-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Asn-Ser-Ser-His-Xaa5-Xaa1-Leu-Cys-Gly;(SEQ ID NO:48)Xaa5-Gln-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Asn-Val-Gly-His-Xaa5-Xaa1-Leu-Cys-Gly;(SEQ ID NO:49)Xaa6-Val-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Asn-Val-Gly-His-Xaa5-Xaa1-Ile-Cys-Gly;(SEQ ID NO:50)Gly-Cys-Cys-Ser-Arg-Xaa5-Xaa5-Cys-Ile-Ala-Asn-Asn-Xaa5-Asp-Leu-Cys;(SEQ ID NO:51)Xaa5-Gln-Cys-Cys-Ser-His-Leu-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:52)Gly-Cys-Cys-Ser-Xaa4-Phe-Asp-Cys-Arg-Met-Met-Phe-Xaa5-Xaa1-Met-Cys-Gly-Xaa3-Arg;(SEQ ID NO:53)Gly-Gly-Cys-Cys-Ser-Phe-Ala-Ala-Cys-Arg-Xaa2-Xaa4-Arg-Xaa5-Xaa1-Met-Cys-Gly;(SEQ ID NO:54)Gly-Gly-Cys-Cys-Phe-His-Xaa5-Val-Cys-Xaa4-Ile-Asn-Leu-Leu-Xaa1-Met-Cys-Arg-Gln-Arg;(SEQ ID NO:55)Ser-Ala-Thr-Cys-Cys-Asn-Xaa4-Xaa5-Xaa5-Cys-Xaa4-Xaa1-Thr-Xaa4-Xaa5-Xaa1-Ser-Cys-Leu;(SEQ ID NO:56)Ala-Cys-Cys-Ala-Xaa4-Xaa5-Xaa5-Cys-Phe-Xaa1-Ala-Xaa4-Xaa5-Xaa1-Arg-Cys-Leu;(SEQ ID NO:57)Asn-Ala-Xaa1-Cys-Cys-Xaa4-Xaa4-Xaa5-Xaa5-Cys-Xaa4-Xaa1-Ala-Xaa4-Xaa5-Xaa1-Ile-Cys-Leu;(SEQ ID NO:170)Xaa1-Cys-Cys-Thr-Asn-Xaa5-Val-Cys-His-Ala-Xaa1-His-Gln-Xaa1-Leu-Cys-Ala-Arg-Arg-Arg;(SEQ ID NO:171)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-His-Leu-Xaa1-His-Ser-Asn-Leu-Cys;(SEQ ID NO:172)Xaa1-Cys-Cys-Thr-Asn-Xaa5-Val-Cys-His-Val-Xaa1-His-Gln-Xaa1-Leu-Cys-Ala-Arg-Arg-Arg;(SEQ ID NO:173)Xaa6-Xaa1-Cys-Cys-Ser-Xaa4-Xaa5-Ala-Cys-Asn-Leu-Asp-His-Xaa5-Xaa1-Leu-Cys;(SEQ ID NO:174)Xaa5-Xaa1-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Asn-Ser-Thr-His-Xaa5-Xaa1-Leu-Cys-Gly;(SEQ ID NO:175)Leu-Asn-Cys-Cys-Met-Ile-Xaa5-Xaa5-Cys-Xaa3-Xaa2-Xaa2-Xaa4-Gly-Asp-Arg-Cys-Ser-Xaa1-Val-Arg;(SEQ ID NO:176)Ala-Phe-Gly-Cys-Cys-Asp-Leu-Ile-Xaa5-Cys-Leu-Xaa1-Arg-Xaa4-Gly-Asn-Arg-Cys-Asn-Xaa1-Val-His;(SEQ ID NO:177)Leu-Gly-Cys-Cys-Asn-Val-Thr-Xaa5-Cys-Xaa3-Xaa1-Xaa2-Xaa4-Gly-Asp-Xaa2-Cys-Asn-Xaa1-Val-Arg;(SEQ ID NO:178)Asp-Xaa1-Cys-Cys-Ser-Asn-Xaa5-Ala-Cys-Arg-Val-Asn-Asn-Xaa5-His-Val-Cys-Arg-Arg-Arg;(SEQ ID NO:179)Leu-Asn-Cys-Cys-Ser-Ile-Xaa5-Gly-Cys-Xaa3-Asn-Xaa1-Xaa4-Xaa2-Asp-Arg-Cys-Ser-Xaa2-Val-Arg;(SEQ ID NO:180)Gly-Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Xaa4-Phe-Asn-Asn-Xaa5-Gln-Met-Cys-Arg;(SEQ ID NO:181)Gly-Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Asn-Leu-Asn-Asn-Xaa5-Gln-Met-Cys-Arg;(SEQ ID NO:182)Gly-Cys-Cys-Ser-His-Xaa5-Xaa5-Cys-Xaa4-Ala-Asn-Asn-Gln-Ala-Xaa4-Cys-Asn;(SEQ ID NO:183)Gly-Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Val-Thr-His-Xaa5-Xaa1-Leu-Cys;(SEQ ID NO:184)Gly-Gly-Cys-Cys-Ser-Xaa4-Xaa5-Ala-Cys-Ser-Val-Xaa1-His-Gln-Asp-Leu-Cys-Asp;(SEQ ID NO:185)Val-Ser-Cys-Cys-Val-Val-Arg-Xaa5-Cys-Xaa3-Ile-Arg-Xaa4-Gln-Xaa1-Xaa1-Cys-Leu-Xaa1-Ala-Asp-Xaa5-Arg-Thr-Leu;(SEQ ID NO:186)Xaa6-Asn-Cys-Cys-Ser-Ile-Xaa5-Gly-Cys-Xaa3-Xaa1-Xaa2-Xaa4-Gly-Asp-Xaa2-Cys-Ser-Xaa1-Val-Arg;(SEQ ID NO:187)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-His-Leu-Xaa1-His-Xaa5-Asn-Ala-Cys;(SEQ ID NO:188)Gly-Cys-Cys-Ser-Asn-Xaa5-Ile-Cys-Xaa4-Phe-Asn-Asn-Xaa5-Arg-Ile-Cys-Arg;(SEQ ID NO:189)Xaa1-Cys-Cys-Ser-Gln-Xaa5-Xaa5-Cys-Arg-Xaa3-Xaa2-His-Xaa5-Xaa1-Leu-Cys-Ser;(SEQ ID NO:190)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ala-Gly-Asn-Asn-Gln-His-Ile-Cys;(SEQ ID NO:191)Gly-Cys-Cys-Ala-Val-Xaa5-Ser-Cys-Arg-Leu-Arg-Asn-Xaa5-Asp-Leu-Cys-Gly-Gly;(SEQ ID NO:192)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asn-Asn-Xaa5-His-Ile-Cys;(SEQ ID NO:193)Thr-Xaa5-Xaa1-Xaa1-Cys-Cys-Xaa5-Asn-Xaa5-Xaa5-Cys-Phe-Ala-Thr-Asn-Ser-Asp-Ile-Cys-Gly;(SEQ ID NO:194)Asp-Ala-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Ser-Gly-Xaa2-His-Gln-Asp-Leu-Cys;(SEQ ID NO:195)Xaa1-Asp-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Ser-Val-Gly-His-Gln-Asp-Leu-Cys;(SEQ ID NO:196)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ala-Gly-Ser-Asn-Ala-His-Ile-Cys;(SEQ ID NO:197)Xaa1-Asp-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Ser-Val-Gly-His-Gln-Asp-Met-Cys;(SEQ ID NO:198)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ala-Gly-Asn-Asn-Xaa5-His-Ile-Cys;(SEQ ID NO:199)Gly-Cys-Cys-Gly-Asn-Xaa5-Ser-Cys-Ser-Ile-His-Ile-Xaa5-Xaa4-Val-Cys-Asn;(SEQ ID NO:200)Thr-Asp-Ser-Xaa1-Xaa1-Cys-Cys-Leu-Asp-Ser-Arg-Cys-Ala-Gly-Gln-His-Gln-Asp-Leu-Cys-Gly;(SEQ ID NO:201)Gly-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Xaa4-Ala-Asn-Asn-Gln-Ala-Xaa4-Cys-Asn;(SEQ ID NO:202)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Val-Asn-Asn-Xaa5-Asp-Ile-Cys;(SEQ ID NO:203)Gly-Xaa2-Cys-Cys-Ile-Asn-Asp-Ala-Cys-Arg-Ser-Xaa2-His-Xaa5-Gln-Xaa4-Cys-Ser;(SEQ ID NO:204)Gly-Cys-Cys-Xaa4-Asn-Ile-Ala-Cys-Arg-Ile-Asn-Asn-Xaa5-Arg-Xaa4-Cys-Arg;(SEQ ID NO:205)Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Arg-Phe-Asn-Xaa4-Xaa5-Xaa2-Xaa4-Cys-Gly;(SEQ ID NO:206)Asp-Xaa1-Cys-Cys-Ala-Ser-Xaa5-Xaa5-Cys-Arg-Leu-Asn-Asn-Xaa5-Xaa4-Val-Cys-His;(SEQ ID NO:207)Gly-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-Xaa3-Gln-Asn-Asn-Ala-Xaa1-Xaa4-Cys-Arg-Xaa1-Ser;(SEQ ID NO:208)Gly-Cys-Cys-Ser-His-Xaa5-Xaa5-Cys-Ala-Gln-Asn-Asn-Gln-Asp-Xaa4-Cys;(SEQ ID NO:209)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ser-Gly-Asn-Asn-Arg-Xaa1-Xaa4-Cys-Arg-Xaa1-Ser;(SEQ ID NO:210)Asp-Xaa5-Cys-Cys-Ser-Xaa4-Xaa5-Asp-Cys-Gly-Ala-Asn-His-Xaa5-Xaa1-Ile-Cys-Gly;(SEQ ID NO:211)Xaa1-Cys-Cys-Ser-Gln-Xaa5-Xaa5-Cys-Arg-Xaa3-Xaa2-His-Xaa5-Xaa1-Leu-Cys-Ser;(SEQ ID NO:212)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Ala-Gly-Asn-Asn-Xaa5-His-Ile-Cys;(SEQ ID NO:213)Gly-Cys-Cys-Ser-Asp-Xaa5-Ser-Cys-Asn-Val-Asn-Asn-Xaa5-Asp-Xaa4-Cys;(SEQ ID NO:214)Xaa1-Xaa1-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-Ser-Val-Gly-His-Gln-Asp-Met-Cys-Arg;(SEQ ID NO:215)Gly-Gly-Cys-Cys-Ser-Asn-Xaa5-Ala-Cys-Leu-Val-Asn-His-Leu-Xaa1-Met-Cys;(SEQ ID NO:216)Arg-Asp-Xaa5-Cys-Cys-Phe-Asn-Xaa5-Ala-Cys-Asn-Val-Asn-Asn-Xaa5-Gln-Ile-Cys;(SEQ ID NO:217)Cys-Cys-Ser-Asp-Xaa5-Ser-Cys-Xaa3-Arg-Leu-His-Ser-Leu-Ala-Cys-Thr-Gly-Ile-Val-Asn-Arg;(SEQ ID NO:218)Cys-Cys-Thr-Asn-Xaa5-Ala-Cys-Leu-Val-Asn-Asn-Ile-Arg-Phe-Cys-Gly;(SEQ ID NO:219)Asp-Xaa1-Cys-Cys-Ser-Asp-Xaa5-Arg-Cys-His-Gly-Asn-Asn-Arg-Asp-His-Cys-Ala;(SEQ ID NO:220)Asp-Cys-Cys-Ser-His-Xaa5-Leu-Cys-Arg-Leu-Phe-Val-Xaa5-Gly-Leu-Cys-Ile;(SEQ ID NO:221)Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Xaa2-Val-Arg-Xaa4-Xaa5-Asp-Leu-Cys-Arg;(SEQ ID NO:222)Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asn-Asn-Xaa5-His-Ile-Cys;(SEQ ID NO:223)Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Xaa2-Val-Arg-Xaa4-Ser-Asp-Met-Cys;(SEQ ID NO:224)Gly-Gly-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Xaa2-Val-His-Phe-Xaa5-His-Ser-Cys;(SEQ ID NO:225)Val-Cys-Cys-Ser-Asn-Xaa5-Val-Cys-His-Val-Asp-His-Xaa5-Xaa1-Leu-Cys-Arg-Arg-Arg-Arg;(SEQ ID NO:226)Gly-Cys-Cys-Ser-His-Xaa5-Val-Cys-Asn-Leu-Ser-Asn-Xaa5-Gln-Ile-Cys-Arg;(SEQ ID NO:227)Xaa6-Xaa1-Cys-Cys-Ser-His-Xaa5-Ala-Cys-Asn-Val-Asp-His-Xaa5-Xaa1-Ile-Cys-Arg;(SEQ ID NO:228)Gly-Cys-Cys-Ser-Asn-Xaa5-Ala-Cys-Leu-Val-Asn-His-Ile-Arg-Phe-Cys-Gly;(SEQ ID NO:229)Asp-Cys-Cys-Asp-Asp-Xaa5-Ala-Cys-Thr-Val-Asn-Asn-Xaa5-Gly-Leu-Cys-Thr;and(SEQ ID NO:230)Gly-Cys-Cys-Ser-Asn-Xaa5-Xaa5-Cys-Ile-Ala-Xaa2-Asn-Xaa5-His-Met-Cys-Gly-Gly-Arg-Arg,


wherein Xaa1 is Glu or γ-carboxy-Glu (Gla); Xaa2 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa3 is Trp (D or L), halo-Trp or neo-Trp; Xaa4 is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa5 is Pro or hydroxy-Pro; Xaa6 is Gln or pyro-Glu; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr and bromine for Trp. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe and Trp residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to the following α-conotoxin peptides of general formula III:

    • SmI: SEQ ID NO:22, wherein Xaa1 is Glu and Xaa5 is Pro;
    • OB-29: SEQ ID NO:23, wherein Xaa1 is Glu, Xaa3 is Tyr and Xaa5 is Pro;
    • Tx1.1: SEQ ID NO:24, wherein Xaa1 is Glu and Xaa5 is Pro;
    • R1.1A: SEQ ID NO:25, wherein Xaa1 is Glu and Xaa5 is Pro;
    • R1.1B: SEQ ID NO:26, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Om-9: SEQ ID NO:27, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Om-10: SEQ ID NO:28, wherein Xaa5 is Pro;
    • Om-21: SEQ ID NO:29, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Om-25: SEQ ID NO:30, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Om-27: SEQ ID NO:31, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Om-28: SEQ ID NO:32, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Bt1.2: SEQ ID NO:33, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Bt1.4: SEQ ID NO:34, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Da1.1: SEQ ID NO:35, wherein Xaa1 is Glu and Xaa5 is Pro; OB-20: SEQ ID NO:36, wherein Xaa1 is Glu, Xaa2 is Lys and Xaa5 is Pro;
    • TI: SEQ ID NO:37, wherein Xaa1 is Glu and Xaa5 is Pro;
    • TIB: SEQ ID NO:38, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Pn1.1: SEQ ID NO:39, wherein Xaa5 is Pro;
    • Pn1.2: SEQ ID NO:40, wherein Xaa1 is Glu and Xaa5 is Pro;
    • T1: SEQ ID NO:41, wherein Xaa2 is Lys and Xaa5 is Pro;
    • TIA: SEQ ID NO:43, wherein Xaa5 is Pro;
    • Da1.2: SEQ ID NO:44, wherein Xaa5 is Pro;
    • Cr1.2: SEQ ID NO:45, wherein Xaa1 is Glu and Xaa5 is Pro;
    • SI1.2: SEQ ID NO:46, wherein Xaa1 is Glu, Xaa2 is Lys and Xaa5 is Pro;
    • Tx1.3: SEQ ID NO:47, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Da1.3: SEQ ID NO:48, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Da1.4: SEQ ID NO:49, wherein Xaa1 is Glu, Xaa5 is Pro and Xaa6 is Gln;
    • Tx1.2: SEQ ID NO:50, wherein Xaa5 is Pro;
    • Om-35: SEQ ID NO:51, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Sl1.1: SEQ ID NO:52, wherein Xaa1 is Glu, Xaa3 is Trp, Xaa4 is Tyr and Xaa5 is Pro;
    • Sl1.6: SEQ ID NO:53, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Sl1.7: SEQ ID NO:54, wherein Xaa1 is Glu Xaa4 is Tyr and Xaa5 is Pro;
    • Bt1.1: SEQ ID NO:55, wherein Xaa1 is Glu Xaa4 is Tyr and Xaa5 is Pro;
    • Bt:1.3: SEQ ID NO:56, wherein Xaa1 is Glu Xaa4 is Tyr and Xaa5 is Pro;
    • Bt1.5: SEQ ID NO:57, wherein Xaa1 is Glu Xaa4 is Tyr and Xaa5 is Pro;
    • A1.4: SEQ ID NO:170, wherein Xaa1 is Glu and Xaa5 is Pro;
    • A1.5: SEQ ID NO:171, wherein Xaa1 is Glu and Xaa5 is Pro;
    • A1.6: SEQ ID NO:172, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Af1.1: SEQ ID NO:173, wherein Xaa1 is Glu Xaa4 is Tyr, Xaa5 is Pro and Xaa6 is Gln;
    • Af1.2: SEQ ID NO:174, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Ar1.2: SEQ ID NO:175, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Try and Xaa5 is Pro;
    • Ar1.3: SEQ ID NO:176, wherein Xaa1 is Glu, Xaa4 is Tyr and Xaa5 is Pro;
    • Ar1.4: SEQ ID NO:177, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Try and Xaa5 is Pro;
    • Ar1.5: SEQ ID NO:178, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Ar1.6: SEQ ID NO:179, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Try and Xaa5 is Pro;
    • Ay1.2: SEQ ID NO:180, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Ay1.3: SEQ ID NO:181, wherein Xaa5 is Pro;
    • Bn1.4: SEQ ID NO:182, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Bt1.8: SEQ ID NO:183, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Bt1.9: SEQ ID NO:184, wherein Xaa1 is Glu, Xaa4 is Tyr and Xaa5 is Pro;
    • Ca1.3: SEQ ID NO:185, wherein Xaa1 is Glu, Xaa3 is Trp, Xaa4 is Try and Xaa5 is Pro;
    • Ca1.4: SEQ ID NO:186, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp, Xaa4 is Try, Xaa5 is Pro and Xaa6 is Gln;
    • C1.2: SEQ ID NO:187, wherein Xaa1 is Glu and Xaa5 is Pro;
    • C1.3: SEQ ID NO:188, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Ep1.2: SEQ ID NO:189, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp and Xaa5 is Pro;
    • G1.1: SEQ ID NO:190, wherein Xaa5 is Pro;
    • G1.3: SEQ ID NO:191, wherein Xaa5 is Pro;
    • Im1.3: SEQ ID NO:192, wherein Xaa5 is Pro;
    • Lv1.2: SEQ ID NO:193, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Lv1.3: SEQ ID NO:194, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Lv1.4: SEQ ID NO:195, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Lv1.6: SEQ ID NO:196, wherein Xaa5 is Pro;
    • Lv1.7: SEQ ID NO:197, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Lv1.8: SEQ ID NO:198, wherein Xaa5 is Pro;
    • Lv1.9: SEQ ID NO:199, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Lv1.10: SEQ ID NO:200, wherein Xaa1 is Glu;
    • Mr1.3: SEQ ID NO:201, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Mr1.4: SEQ ID NO:202, wherein Xaa5 is Pro;
    • Ms 1.1: SEQ ID NO:203, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Ms1.6: SEQ ID NO:204, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • O1.1: SEQ ID NO:205, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • O1.2: SEQ ID NO:206, wherein Xaa1 is Glu, Xaa4 is Tyr and Xaa5 is Pro;
    • O1.4: SEQ ID NO:207, wherein Xaa1 is Glu, Xaa3 is Trp, Xaa4 is Tyr and Xaa5 is Pro;
    • O1.7: SEQ ID NO:208, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • O1.8: SEQ ID NO:209, wherein Xaa1 is Glu, Xaa4 is Tyr and Xaa5 is Pro;
    • Om1.2: SEQ ID NO:210, wherein Xaa1 is Glu, Xaa4 is Tyr and Xaa5 is Pro;
    • Om1.3: SEQ ID NO:211, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa3 is Trp and Xaa5 is Pro;
    • Om1.4: SEQ ID NO:212, wherein Xaa5 is Pro;
    • Om1.5: SEQ ID NO:213, wherein Xaa4 is Tyr and Xaa5 is Pro;
    • Om1.6: SEQ ID NO:214, wherein Xaa1 is Glu and Xaa5 is Pro;
    • P1.4: SEQ ID NO:215, wherein Xaa1 is Glu and Xaa5 is Pro;
    • P1.5: SEQ ID NO:216, wherein Xaa5 is Pro;
    • P1.6: SEQ ID NO:217, wherein Xaa3 is Trp and Xaa5 is Pro;
    • P1.8: SEQ ID NO:218, wherein Xaa5 is Pro;
    • Rg1.1: SEQ ID NO:219, wherein Xaa1 is Glu and Xaa5 is Pro;
    • Rg1.3: SEQ ID NO:220, wherein Xaa5 is Pro;
    • Rg1.4: SEQ ID NO:221, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Rg1.5: SEQ ID NO:222, wherein Xaa5 is Pro;
    • Rg1.8: SEQ ID NO:223, wherein Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro;
    • Sm1.4: SEQ ID NO:224, wherein Xaa2 is Lys and Xaa5 is Pro;
    • Sm1.5: SEQ ID NO:225, wherein Xaa1 is Glu and Xaa5 is Pro;
    • S1.5: SEQ ID NO:226, wherein Xaa5 is Pro;
    • Tx1.5: SEQ ID NO:227, wherein Xaa1 is Glu, Xaa5 is Pro and Xaa6 is Gln;
    • T1.1: SEQ ID NO:228, wherein Xaa5 is Pro;
    • Vr1.3: SEQ ID NO:229, wherein Xaa5 is Pro; and
    • Tb: SEQ ID NO:230, wherein Xaa2 is Lys and Xaa5 is Pro.


      The C-terminus preferably contains a carboxyl group for the peptides OB-29, Tx1.1, R1.1A, R1.1B, Om-9, Om-10, Om-21, Om-25, Om-27, Om-28, Cr1.2, Om-35, Bt1.1, Bt1.3, Bt1.5, A1.4, A1.6, Ar1.2, Ar1.3, Ar1.4, Ar1.5, Ar1.6, Ca1.3, Ca1.4, Ep1.2, Lv1.9, 01.2, Om1.3, Om1.6, P1.6, Rg1.1, Rg1.3, Rg1.4, Sm1.5, Tx1.5 and Vr1.3.


      The C-terminus of the other peptides preferably contains an amide group.


The present invention is also directed to the novel specific α-conotoxin peptides having the formulas:

(SEQ ID NO:231)Cys-Cys-Thr-Ile-Xaa5-Ser-Cys-Xaa4-Xaa1-Xaa2-Xaa2-Xaa2-Ile-Xaa2-Ala-Cys-Val-Pheand(SEQ ID NO:232)Gly-Cys-Cys-Gly-Asn-Xaa5-Ala-Cys-Ser-Gly-Ser-Ser-Xaa2-Asp-Ala-Xaa5-Ser-Cys,


wherein Xaa1 is Glu or γ-carboxy-Glu (Gla); Xaa2 is Lys, N-methyl-Lys, N,N-dimethyl-Lys or N,N,N-trimethyl-Lys; Xaa4 is Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr or nitro-Tyr; and Xaa5 is Pro or hydroxy-Pro; and the C-terminus contains a carboxyl or amide group. The halo is preferably bromine, chlorine or iodine, more preferably iodine for Tyr. In addition, the His residues may be substituted with halo-His; the Arg residues may be substituted by Lys, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Lys residues may be substituted by Arg, ornithine, homoarginine, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; the Tyr residues may be substituted with any unnatural hydroxy containing amino acid; the Ser residues may be substituted with Thr; the Thr residues may be substituted with Ser; and the Phe residues may be substituted with any unnatural aromatic amino acid. The Cys residues may be in D or L configuration and may optionally be substituted with homocysteine (D or L). The Tyr residues may be substituted with the 3-hydroxyl or 2-hydroxyl isomers and corresponding O-sulpho- and O-phospho-derivatives. The acidic amino acid residues may be substituted with any synthetic acidic bioisoteric amino acid surrogate, e.g., tetrazolyl derivatives of Gly and Ala.


More specifically, the present invention is directed to the following α-conotoxin peptides:

    • G1.2: SEQ ID NO:231, wherein Xaa1 is Glu, Xaa2 is Lys, Xaa4 is Tyr and Xaa5 is Pro; and
    • Rg1.12: SEQ ID NO:232, wherein Xaa2 is Lys and Xaa5 is Pro.


      The C-terminus of G1.2 preferably contains a carboxyl group, and the C-terminus of Rg1.12 preferably contains an amide group.


Examples of unnatural aromatic amino acid include, but are not limited to, such as nitro-Phe, 4-substituted-Phe wherein the substituent is C1-C3 alkyl, carboxyl, hydroxymethyl, sulphomethyl, halo, phenyl, —CHO, —CN, —SO3H and —NHAc. Examples of unnatural hydroxy containing amino acid, include, but are not limited to, such as 4-hydroxymethyl-Phe, 4-hydroxyphenyl-Gly, 2,6-dimethyl-Tyr and 5-amino-Tyr. Examples of unnatural basic amino acids include, but are not limited to, N-1-(2-pyrazolinyl)-Arg, 2-(4-piperinyl)-Gly, 2-(4-piperinyl)-Ala, 2-[3-(2S)pyrrolininyl)-Gly and 2-[3-(2S)pyrrolininyl)-Ala. These and other unnatural basic amino acids, unnatural hydroxy containing amino acids or unnatural aromatic amino acids are described in Building Block Index, Version 3.0 (1999 Catalog, pages 4-47 for hydroxy containing amino acids and aromatic amino acids and pages 66-87 for basic amino acids; see also website “amino-acids.com”), incorporated herein by reference, by and available from RSP Amino Acid Analogues, Inc., Worcester, Mass.


Optionally, in the peptides of general formulas I, II and III and the specific peptides described above, the Asn residues may be modified to contain an N-glycan and the Ser and Thr residues may be modified to contain an O-glycan. In accordance with the present invention, a glycan shall mean any N-, S- or O-linked mono-, di-, tri-, poly- or oligosaccharide that can be attached to any hydroxy, amino or thiol group of natural or modified amino acids by synthetic or enzymatic methodologies known in the art. The monosaccharides making up the glycan can include D-allose, D-altrose, D-glucose, D-mannose, D-gulose, D-idose, D-galactose, D-talose, D-galactosamine, D-glucosamine, D-N-acetyl-glucosamine (GlcNAc), D-N-acetyl-galactosamine (GalNAc), D-fucose or D-arabinose. These saccharides may be structurally modified, e.g., with one or more O-sulfate, O-phosphate, O-acetyl or acidic groups, such as sialic acid, including combinations thereof. The glycan may also include similar polyhydroxy groups, such as D-penicillamine 2,5 and halogenated derivatives thereof or polypropylene glycol derivatives. The glycosidic linkage is beta and 1-4 or 1-3, preferably 1-3. The linkage between the glycan and the amino acid may be alpha or beta, preferably alpha and is 1−.


Core O-glycans have been described by Van de Steen et al. (1998), incorporated herein by reference. Mucin type O-linked oligosaccharides are attached to Ser or Thr (or other hydroxylated residues of the present peptides) by a GalNAc residue. The monosaccharide building blocks and the linkage attached to this first GalNAc residue define the “core glycans,” of which eight have been identified. The type of glycosidic linkage (orientation and connectivities) are defined for each core glycan. Suitable glycans and glycan analogs are described further in U.S. Ser. No. 09/420,797, filed 19 Oct. 1999 (now U.S. Pat. No. 6,369,193) and in PCT Application No. PCT/US99/24380, filed 19 Oct. 1999, both incorporated herein by reference. A preferred glycan is Gal(β1→3)GalNAc(α1→).


Optionally, in the peptides of general formulas I and II and the specific peptides described above, pairs of Cys residues may be replaced pairwise with Ser/(Glu or Asp) or Lys/(Glu or Asp) combinations. Sequential coupling by known methods (Barnay et al., 2000; Hruby et al., 1994; Bitan et al., 1997) allows replacement of native Cys bridges with lactam bridges.


The present invention is further directed to propeptides and nucleic acid sequences encoding the propeptides or peptides as described in further detail herein.







DETAILED DESCRIPTION OF THE INVENTION

The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.


The present invention, in another aspect, relates to a pharmaceutical composition comprising an effective amount of an α-conotoxin peptide. Such a pharmaceutical composition has the capability of acting as antagonists for nicotinic acetylcholine receptors. In one aspect, the α-conotoxins with specificity for neuromuscular junction nicotinic acetylcholine receptors are used as neuromuscular blocking agents for use in conjunction with surgery, as disclosed in U.S. patent application Ser. No. 09/488,799, filed 21 Jan. 2000, incorporated by reference herein. In a second aspect, additional α-conotoxins and uses for them have been described in U.S. Pat. Nos. 4,447,356 (Olivera et al., 1984); 5,432,155; 5,514,774, each incorporated herein by reference.


In a third aspect additional uses for α-conotoxins are described in U.S. Ser. No. 09/219,446, filed 22 Dec. 1998, incorporated herein by reference. In this application, α-conotoxins with specificity for neuronal nicotinic acetylcholine receptors are used for treating disorders regulated at neuronal nicotinic acetylcholine receptors. Such disorders include, but are not limited to, cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders (such as bipolar disorder, unipolar depression, dysthymia and seasonal effective disorder) and small cell lung carcinoma, as well as the localization of small cell lung carcinoma.


The α-conotoxin peptides described herein are sufficiently small to be chemically synthesized. General chemical syntheses for preparing the foregoing α-conotoxin peptides are described hereinafter. Various ones of the α-conotoxin peptides can also be obtained by isolation and purification from specific Conus species using the technique described in U.S. Pat. No. 4,447,356 (Olivera et al., 1984), the disclosure of which is incorporated herein by reference.


Although the α-conotoxin peptides of the present invention can be obtained by purification from cone snails, because the amounts of α-conotoxin peptides obtainable from individual snails are very small, the desired substantially pure α-conotoxin peptides are best practically obtained in commercially valuable amounts by chemical synthesis using solid-phase strategy. For example, the yield from a single cone snail may be about 10 micrograms or less of α-conotoxin peptide. By “substantially pure” is meant that the peptide is present in the substantial absence of other biological molecules of the same type; it is preferably present in an amount of at least about 85% purity and preferably at least about 95% purity. Chemical synthesis of biologically active α-conotoxin peptides depends of course upon correct determination of the amino acid sequence.


The α-conotoxin peptides can also be produced by recombinant DNA techniques well known in the art. Such techniques are described by Sambrook et al. (1989). The peptides produced in this manner are isolated, reduced if necessary, and oxidized to form the correct disulfide bonds.


One method of forming disulfide bonds in the conotoxin peptides of the present invention is the air oxidation of the linear peptides for prolonged periods under cold room temperatures or at room temperature. This procedure results in the creation of a substantial amount of the bioactive, disulfide-linked peptides. The oxidized peptides are fractionated using reverse-phase high performance liquid chromatography (HPLC) or the like, to separate peptides having different linked configurations. Thereafter, either by comparing these fractions with the elution of the native material or by using a simple assay, the particular fraction having the correct linkage for maximum biological potency is easily determined. However, because of the dilution resulting from the presence of other fractions of less biopotency, a somewhat higher dosage may be required.


The peptides are synthesized by a suitable method, such as by exclusively solid-phase techniques, by partial solid-phase techniques, by fragment condensation or by classical solution couplings.


In conventional solution phase peptide synthesis, the peptide chain can be prepared by a series of coupling reactions in which constituent amino acids are added to the growing peptide chain in the desired sequence. Use of various coupling reagents, e.g., dicyclohexylcarbodiimide or diisopropylcarbonyldimidazole, various active esters, e.g., esters of N-hydroxyphthalimide or N-hydroxy-succinimide, and the various cleavage reagents, to carry out reaction in solution, with subsequent isolation and purification of intermediates, is well known classical peptide methodology. Classical solution synthesis is described in detail in the treatise, “Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden,” (1974). Techniques of exclusively solid-phase synthesis are set forth in the textbook, “Solid-Phase Peptide Synthesis,” (Stewart and Young, 1969), and are exemplified by the disclosure of U.S. Pat. No. 4,105,603 (Vale et al., 1978). The fragment condensation method of synthesis is exemplified in U.S. Pat. No. 3,972,859 (1976). Other available syntheses are exemplified by U.S. Pat. No. 3,842,067 (1974) and 3,862,925 (1975). The synthesis of peptides containing γ-carboxyglutamic acid residues is exemplified by Rivier et al. (1987), Nishiuchi et al. (1993) and Zhou et al. (1996).


Common to such chemical syntheses is the protection of the labile side chain groups of the various amino acid moieties with suitable protecting groups which will prevent a chemical reaction from occurring at that site until the group is ultimately removed. Usually also common is the protection of an α-amino group on an amino acid or a fragment while that entity reacts at the carboxyl group, followed by the selective removal of the α-amino protecting group to allow subsequent reaction to take place at that location. Accordingly, it is common that, as a step in such a synthesis, an intermediate compound is produced which includes each of the amino acid residues located in its desired sequence in the peptide chain with appropriate side-chain protecting groups linked to various ones of the residues having labile side chains.


As far as the selection of a side chain amino protecting group is concerned, generally one is chosen which is not removed during deprotection of the α-amino groups during the synthesis. However, for some amino acids, e.g., His, protection is not generally necessary. In selecting a particular side chain protecting group to be used in the synthesis of the peptides, the following general rules are followed: (a) the protecting group preferably retains its protecting properties and is not split off under coupling conditions, (b) the protecting group should be stable under the reaction conditions selected for removing the α-amino protecting group at each step of the synthesis, and (c) the side chain protecting group must be removable, upon the completion of the synthesis containing the desired amino acid sequence, under reaction conditions that will not undesirably alter the peptide chain.


It should be possible to prepare many, or even all, of these peptides using recombinant DNA technology. However, when peptides are not so prepared, they are preferably prepared using the Merrifield solid-phase synthesis, although other equivalent chemical syntheses known in the art can also be used as previously mentioned. Solid-phase synthesis is commenced from the C-terminus of the peptide by coupling a protected α-amino acid to a suitable resin. Such a starting material can be prepared by attaching an α-amino-protected amino acid by an ester linkage to a chloromethylated resin or a hydroxymethyl resin, or by an amide bond to a benzhydrylamine (BHA) resin or paramethylbenzhydrylamine (MBHA) resin. Preparation of the hydroxymethyl resin is described by Bodansky et al. (1966). Chloromethylated resins are commercially available from Bio Rad Laboratories (Richmond, Calif.) and from Lab. Systems, Inc. The preparation of such a resin is described by Stewart and Young (1969). BHA and MBHA resin supports are commercially available, and are generally used when the desired polypeptide being synthesized has an unsubstituted amide at the C-terminus. Thus, solid resin supports may be any of those known in the art, such as one having the formulae —O—CH2-resin support, —NH BHA resin support, or —NH-MBHA resin support. When the unsubstituted amide is desired, use of a BHA or MBHA resin is preferred, because cleavage directly gives the amide. In case the N-methyl amide is desired, it can be generated from an N-methyl BHA resin. Should other substituted amides be desired, the teaching of U.S. Pat. No. 4,569,967 (Kornreich et al., 1986) can be used, or should still other groups than the free acid be desired at the C-terminus, it may be preferable to synthesize the peptide using classical methods as set forth in the Houben-Weyl text (1974).


The C-terminal amino acid, protected by Boc or Fmoc and by a side-chain protecting group, if appropriate, can be first coupled to a chloromethylated resin according to the procedure set forth in K. Horiki et al. (1978), using KF in DMF at about 60° C. for 24 hours with stirring, when a peptide having free acid at the C-terminus is to be synthesized. Following the coupling of the BOC-protected amino acid to the resin support, the α-amino protecting group is removed, as by using trifluoroacetic acid (TFA) in methylene chloride or TFA alone. The deprotection is carried out at a temperature between about 0° C. and room temperature. Other standard cleaving reagents, such as HCl in dioxane, and conditions for removal of specific α-amino protecting groups may be used as described in Schroder & Lubke (1965).


After removal of the α-amino-protecting group, the remaining α-amino- and side chain-protected amino acids are coupled step-wise in the desired order to obtain the intermediate compound defined hereinbefore, or as an alternative to adding each amino acid separately in the synthesis, some of them may be coupled to one another prior to addition to the solid phase reactor. Selection of an appropriate coupling reagent is within the skill of the art. Particularly suitable as a coupling reagent is N,N′-dicyclohexylcarbodiimide (DCC, DIC, HBTU, HATU, TBTU in the presence of HoBt or HoAt).


The activating reagents used in the solid phase synthesis of the peptides are well known in the peptide art. Examples of suitable activating reagents are carbodiimides, such as N,N′-diisopropylcarbodiimide and N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide. Other activating reagents and their use in peptide coupling are described by Schroder & Lubke (1965) and Kapoor (1970).


Each protected amino acid or amino acid sequence is introduced into the solid-phase reactor in about a twofold or more excess, and the coupling may be carried out in a medium of dimethylformamide (DMF): CH2Cl2 (1:1) or in DMF or CH2Cl2 alone. In cases where intermediate coupling occurs, the coupling procedure is repeated before removal of the α-amino protecting group prior to the coupling of the next amino acid. The success of the coupling reaction at each stage of the synthesis, if performed manually, is preferably monitored by the ninhydrin reaction, as described by Kaiser et al. (1970). Coupling reactions can be performed automatically, as on a Beckman 990 automatic synthesizer, using a program such as that reported in Rivier et al. (1978).


After the desired amino acid sequence has been completed, the intermediate peptide can be removed from the resin support by treatment with a reagent, such as liquid hydrogen fluoride or TFA (if using Fmoc chemistry), which not only cleaves the peptide from the resin but also cleaves all remaining side chain protecting groups and also the α-amino protecting group at the N-terminus if it was not previously removed to obtain the peptide in the form of the free acid. If Met is present in the sequence, the Boc protecting group is preferably first removed using trifluoroacetic acid (TFA)/ethanedithiol prior to cleaving the peptide from the resin with HF to eliminate potential S-alkylation. When using hydrogen fluoride or TFA for cleaving, one or more scavengers such as anisole, cresol, dimethyl sulfide and methylethyl sulfide are included in the reaction vessel.


Cyclization of the linear peptide is preferably affected, as opposed to cyclizing the peptide while a part of the peptide-resin, to create bonds between Cys residues. To effect such a disulfide cyclizing linkage, fully protected peptide can be cleaved from a hydroxymethylated resin or a chloromethylated resin support by ammonolysis, as is well known in the art, to yield the fully protected amide intermediate, which is thereafter suitably cyclized and deprotected. Alternatively, deprotection, as well as cleavage of the peptide from the above resins or a benzhydrylamine (BHA) resin or a methylbenzhydrylamine (MBHA), can take place at 0° C. with hydrofluoric acid (HF) or TFA, followed by oxidation as described above.


The peptides are also synthesized using an automatic synthesizer. Amino acids are sequentially coupled to an MBHA Rink resin (typically 100 mg of resin) beginning at the C-terminus using an Advanced Chemtech 357 Automatic Peptide Synthesizer. Couplings are carried out using 1,3-diisopropylcarbodimide in N-methylpyrrolidinone (NMP) or by 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and diethyliso-propylethylamine (DIEA). The FMOC protecting group is removed by treatment with a 20% solution of piperidine in dimethylformamide (DMF). Resins are subsequently washed with DMF (twice), followed by methanol and NMP.


Pharmaceutical compositions containing a compound of the present invention or its pharmaceutically acceptable salts as the active ingredient can be prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, Pa.). Typically, an antagonistic amount of the active ingredient will be admixed with a pharmaceutically acceptable carrier. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral or parenteral. The compositions may further contain antioxidizing agents, stabilizing agents, preservatives and the like.


For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, WO 96/11698.


For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.


The active agent is preferably administered in an therapeutically effective amount. The actual amount administered, and the rate and time-course of administration, will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc., is within the responsibility of general practitioners or specialists, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences. Typically the conopeptides of the present invention exhibit their effect at a dosage range from about 0.001 mg/kg to about 250 mg/kg, preferably from about 0.05 mg/kg to about 100 mg/kg of the active ingredient, more preferably from a bout 0.1 mg/kg to about 75 mg/kg. A suitable dose can be administered in multiple sub-doses per day. Typically, a dose or sub-dose may contain from about 0.1 mg to about 500 mg of the active ingredient per unit dosage form. A more preferred dosage will contain from about 0.5 mg to about 100 mg of active ingredient per unit dosage form. Dosages are generally initiated at lower levels and increased until desired effects are achieved.


Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.


The active agents, which are peptides, can also be administered in a cell based delivery system in which a DNA sequence encoding an active agent is introduced into cells designed for implantation in the body of the patient, especially in the spinal cord region. Suitable delivery systems are described in U.S. Pat. No. 5,550,050 and published PCT Application Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and WO 97/12635. Suitable DNA sequences can be prepared synthetically for each active agent on the basis of the developed sequences and the known genetic code.


EXAMPLES

The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner. Standard techniques well known in the art or the techniques specifically described below were utilized.


Example 1
Isolation of α-Conotoxins

Crude venom was extracted from venom ducts (Cruz et al., 1976), and the components were purified as previously described (Cartier et al., 1996a). The crude extract from venom ducts was purified by reverse phase liquid chromatography (RPLC) using a Vydac C18 semi-preparative column (10×250 mm) and elution with a linear gradient of acetonitrile in 0.1% TFA. Further purification of bioactive peaks was done on a Vydac CIS analytical column (4.6×220 mm) eluted with a gradient of acetonitrile in 0.1% TFA. The effluents were monitored at 220 nm. Peaks were collected, and aliquots were assayed for activity. Activity was monitored by assessing block of α3β4 nAChRs expressed in Xenopus oocytes.


The amino acid sequence of the purified peptides were determined by standard methods. The purified peptides were reduced and alkylated prior to sequencing by automated Edman degradation on an Applied Biosystems 477A Protein Sequencer with a 120A Analyzer (DNA/Peptide Facility, University of Utah) (Martinez et al., 1995; Shon et al., 1994).


In accordance with this method, peptides MII, AuIA, AuIB, AuIC, MAR-1, MAR-2, TI, OB-29, EpI, S1.1, Bn1.1, Bn1.2, Ca1.1, Ca1.2, Cn1.1, Cn1.2 and S1.3 were obtained.


Example 2
Synthesis of Conopeptides

The synthesis of conopeptides, either the mature toxins or the precursor peptides, was separately performed using conventional protection chemistry as described by Cartier et al. (1996). Briefly, the linear chains were built on Rink amide resin by Fmoc procedures with 2-(1H-benzotriol-1-yl)-1,1,3,3,-tetramethyluronium tetrafluoroborated coupling using an ABI model 430A peptide synthesizer with amino acid derivatives purchased from Bachem (Torrance Calif.). Orthogonal protection was used on cysteines: Cys3 and Cys16 were protected as the stable Cys(S-acetamidomethyl), while Cys2 and Cys8 were protected as the acid-labile Cys(S-trityl). After removal of the terminal Fmoc protecting group and cleavage of the peptides from the resins, the released peptides were precipitated by filtering the reaction mixture into −10° C. methyl t-butyl ether, which removed the protecting groups except on Cys3 and Cys16. The peptides were dissolved in 0.1% TFA and 60% acetonitrile and purified by RPLC on a Vydac C18 preparative column (22×250 mm) and eluted at a flow rate of 20 mL/min with a gradient of acetonitrile in 0.1% TFA.


The disulfide bridges in the three conopeptides were formed as described in Cartier et al. (1996). Briefly, the disulfide bridges between Cys2 and Cys8 were formed by air oxidation which was judged to be complete by analytical RPLC. The monocyclic peptides were purified by RPLC on a Vydac C18 preparative column (22×250 mm) and eluted with a gradient of acetonitrile in 0.1% TFA. Removal of S-acetamidomethyl groups and closure of the disulfide bridge between Cys3 and Cys16 was carried out simultaneously be iodine oxidation. The cyclic peptides were purified by RPLC on a Vydac C18 preparative column (22×250 mm) and eluted with a gradient of acetonitrile in 0.1% TFA.


Example 3
Isolation of DNA Encoding α-Conotoxins

DNA coding for α-conotoxins was isolated and cloned in accordance with conventional techniques using general procedures well known in the art, such as described in Olivera et al. (1996). Alternatively, cDNA libraries was prepared from Conus venom duct using conventional techniques. DNA from single clones was amplified by conventional techniques using primers which correspond approximately to the M13 universal priming site and the M13 reverse universal priming site. Clones having a size of approximately 300 nucleotides were sequenced and screened for similarity in sequence to known α-conotoxins. The DNA sequences and encoded propeptide or peptide sequences are set forth in Tables 1-134.

TABLE 1DNA Sequence (SEQ ID NO:58) and Protein Sequence(SEQ ID NO:59) of MIIatg ttc acc gtg ttt ctg ttg gtt gtc ttg gca accMet Phe Thr Val Phe Leu Leu Val Val Leu Ala Thract gtc gtt tcc ttc cct tca gat cgt gca tct gatThr Val Val Ser Phe Pro Ser Asp Arg Ala Ser Aspggc agg aat gcc gca gcc aac gac aaa gcg tct gacGly Arg Asn Ala Ala Ala Asn Asp Lys Ala Ser Aspgtg atc acg ctg gcc ctc aag gga tgc tgt tcc aacVal Ile Thr Leu Ala Leu Lys Gly Cys Cys Ser Asncct gtc tgt cac ttg gag cat tca aac ctt tgt ggtPro Val Cys His Leu Glu His Ser Asn Leu Cys Glyaga aga cgc tgatgctcca ggaccctctg aaccacgacgArg Arg Argttcgagca










TABLE 2








DNA Sequence (SEQ ID NO:60) and Protein Sequence



(SEQ ID NO:61) of AuIA
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca tat gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc agg aag gac gca gag tat ggc ctg atc gct ctg


Gly Arg Lys Asp Ala Ala Ser Gly Leu Ile Ala Leu





acc atc aag gga tgc tgt tat tat cat ccc tgt ttc


Thr Ile Lys Gly Cys Cys Ser Tyr Pro Pro Cys Phe





gag act aat tca gac tat tgt ggt tgacgacgct


Ala Thr Asn Ser Asp Tyr Cys Gly





gatgctccag gaccctctga accacgacgt

















TABLE 3








DNA Sequence (SEQ ID NO:62) and Protein Sequence



(SEQ ID NO:63) of AuIB
















atg ttc acc gtg ttt ctg ttg gtc gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca tat gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc agg aag gac gca gag tat ggc ctg att gct ctg


Gly Arg Lys Asp Ala Ala Ser Gly Leu Ile Ala Leu





acc atg aag gga tgc tgt tat tat cat ccc tgt ttc


Thr Met Lys Gly Cys Cys Ser Tyr Pro Pro Cys Phe





gag act aat cca gac tgt ggt cga cga agc tgatgctcca


Ala Thr Asn Pro Asp Cys Gly Arg Arg Arg





ggaccctctg aaccacgacg t

















TABLE 4








DNA Sequence (SEQ ID NO:64) and Protein Sequence



(SEQ ID NO:65) of Tx1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc tat tca ggt cgt agt aca ttt


Thr Val Val Ser Phe Ser Ser Gly Arg Ser Thr Phe





cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg


Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc agt ctg act gac agg aga cca gaa tgc tgt agt


Val Ser Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser





gat cct cgc tgt aac tcg agt cat cca gaa ctt tgt


Asp Pro Arg Cys Asn Ser Ser His Pro Glu Leu Cys





ggt gga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Gly Gly Arg Arg

















TABLE 5








DNA Sequence (SEQ ID NO:66) and Protein Sequence



(SEQ ID NO:67) of Tx1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





gcc gtc gtt tcc ttc act tca gat cgt gca tct gat


Ala Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





gac ggg aaa gcc gct gcg tct gac ctg atc act ctg


Asp Gly Lys Ala Ala Ala Ser Asp Leu Ile Thr Leu





acc atc aag gga tgc tgt tct cgt cct ccc tgt atc


Thr Ile Lys Gly Cys Cys Ser Arg Pro Pro Cys Ile





gcg aat aat cca gac ttg tgt ggt tgacgacgct


Ala Asn Asn Pro Asp Leu Cys Gly





gatgctccag aacggtctga accacgacgt tcgagcaatg





ttcaccgtgt ttctgttggt tgtctt

















TABLE 6








DNA Sequence (SEQ ID NO:68) and Protein Sequence



(SEQ ID NO:69) of Tx1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca ggt cgt agt aca ttt


Thr Val Val Ser Phe Thr Ser Gly Arg Ser Thr Phe





cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg


Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc agt ctg act gac agg aga cca caa tgc tgt tct


Val Ser Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser





cat cct gcc tgt aac gta gat cat cca gaa att tgt


His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys





cgt tgaagacgct gatgctccag gaccctctga accacgacgt


Arg

















TABLE 7








DNA Sequence (SEQ ID NO:70) and Protein Sequence



(SEQ ID NO:71) of R1.1A
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca ggt cgt cgt aca ttt


Thr Val Val Ser Phe Thr Ser Gly Arg Arg Thr Phe





cat ggc agg aat gcc gca gcc aaa gcg tct ggc ctg


His Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc agt ctg act gac agg aga cca gaa tgc tgt tct


Val Ser Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser





cat cct gcc tgt aac gta gat cat cca gaa att tgt


His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys





cgt tgaagacgct gatgctccag gaccctctga accacgacgt


Arg

















TABLE 8








DNA Sequence (SEQ ID NO:72) and Protein Sequence



(SEQ ID NO:73) of R1.1B
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca ggt cgt agt aca ttt


Thr Val Val Ser Phe Thr Ser Gly Arg Ser Thr Phe





cgt ggc agg aat gcc gca gcc aaa gcg tct ggc ctg


Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc agt ctg act gac agg aga cca caa tgc tgt tct


Val Ser Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser





cat cct gcc tgt aac gta gat cat cca gaa att tgc


His Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys





gat tgaagacgct gatgctccag gaccctctga accacgacgt


Asp

















TABLE 9








DNA Sequence (SEQ ID NO:74) and Protein Sequence



(SEQ ID NO:75) of S1.1
















atg ttc act gtg ttt ctg ttg gtt gtc ttg gca atc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Ile





act gtc gtt tcc ttc cat tta gat cgt gaa tat gat


Thr Val Val Ser Phe Pro Leu Asp Arg Glu Ser Asp





ggc gag aat gcc gaa gcc agc acc cac gat cat gag


Gly Ala Asn Ala Glu Ala Arg Thr His Asp His Glu





aag cac gca ctg gac cgg aat gga tgc tgt agg aat


Lys His Ala Lcu Asp Arg Asn Gly Cys Cys Arg Asn





cat gcc tgt gag agc cac aga tgt ggt tgacgacgct


Pro Ala Cys Glu Ser His Arg Cys Gly





gatgctccag gaccctctga accacgacgt tcgagca

















TABLE 10








DNA Sequence (SEQ ID NO:76) and Protein Sequence



(SEQ ID NO:77) of Bn1.1
















atg ttc acc atg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Met Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc gct tca gat cgt gca tct gat


Thr Val Val Ser Phe Ala Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc aag gac aaa gcg tct gac


Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala Ser Asp





ctg gtc gct ctg acc gtc aag gga tgc tgt tct cat


Leu Val Ala Leu Thr Val Lys Gly Cys Cys Ser His





cct gcc tgt agc gtg aat aat cca gac att tgt ggt


Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys Gly





tgaagacgct gatgctccag gaccctctga accacgacgt





tcgagca

















TABLE 11








DNA Sequence (SEQ ID NO:78) and Protein Sequence



(SEQ ID NO:79) of Bn1.2
















aaa gaa tgc tgt act cat act gcc tgt cac gtg agt



Lys Glu Cys Cys Thr His Pro Ala Cys His Val Ser





cat cca gaa ctc tgt ggt tgaaaagcga cgtgacgctc


His Pro Glu Leu Cys Gly





caggaccctc tgaaccacga cgttcgagca

















TABLE 12








DNA Sequence (SEQ ID NO:80) and Protein Sequence



(SEQ ID NO:81) of Bn1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca act



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





gct gtt ctt cca gtc act tta gat cgt gca tct gat


Ala Val Leu Pro Val Thr Leu Asp Arg Ala Ser Asp





gga agg aat gca gca gcc aac gcc aaa acg cct cgc


Gly Arg Asn Ala Ala Ala Asn Ala Lys Thr Pro Arg





ctg atc gcg cca ttc atc agg gat tat tgc tgt cat


Leu Ile Ala Pro Phe Ile Arg Asp Tyr Cys Cys His





aga ggt ccc tgt atg gta tgg tgt ggt tgaagccgct


Arg Gly Pro Cys Met Val Trp Cys Gly





gctgctccag gaccctctga accac

















TABLE 13








DNA Sequence (SEQ ID NO:82) and Protein Sequence



(SEQ ID NO:83) of Ca1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtg gtt tcc ttc act tca gat cgt gct tct gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc aac gcg ttt gac ctg atc


Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp Leu Ile





gct ctg atc gcc agg caa aat tgc tgt agc att ccc


Ala Leu Ile Ala Arg Gin Asn Cys Cys Ser Ile Pro





agc tgt tgg gag aaa tat aaa tgt agt taa


Ser Cys Trp Glu Lys Tyr Lys Cys Ser

















TABLE 14








DNA Sequence (SEQ ID NO:84) and Protein Sequence



(SEQ ID NO:85) of Ca1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtg gtt tcc ttc act tca gat cgt gcg tct gaa


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Glu





ggc agg aat gct gca gcc aag gac aaa gcg tct gac


Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala Ser Asp





ctg gtg gct ctg aca gtc agg gga tgc tgt gcc att


Leu Val Ala Leu Thr Val Arg Gly Cys Cys Ala Ile





cgt gaa tgt cgc ttg cag aat gca gcg tat tgt ggt


Arg Glu Cys Arg Leu Gln Asn Ala Ala Tyr Cys Gly





gga ata tac tgatgctcca ggaccctctg aaccacgacg


Gly Ile Tyr

















TABLE 15








DNA Sequence (SEQ ID NO:86) and Protein Sequence



(SEQ ID NO:87) of TIB
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat att gca act gag


Thr Val Val Ser Phe Pro Ser Asp Ile Ala Thr Glu





ggc agg aat gcc gca gcc aaa gcg ttt gac ctg ata


Gly Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Ile





tct tcg atc gtc aag aaa gga tgc tgt tcc cat cct


Ser Ser Ile Val Lys Lys Gly Cys Cys Ser His Pro





gcc tgt tcg ggg aat aat cca gaa ttt tgt cgt caa


Ala Cys Ser Gly Asn Asn Pro Glu Phe Cys Arg Gln





ggt cgc tgatgctcca ggaccctctg aaccacgacg t

















TABLE 16








DNA Sequence (SEQ ID NO:88) and Protein Sequence



(SEQ ID NO:89) of TIA
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat ata gca act gag


Thr Val Val Ser Phe Pro Ser Asp Ile Ala Thr Glu





ggc agg aat gcc gca gcc aaa gcg ttt gac ctg ata


Gly Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Ile





tct tcg atc gtc agg aaa gga tgc tgt tcc aat ccc


Ser Ser Ile Val Arg Lys Gly Cys Cys Ser Asn Pro





gcc tgt gcg ggg aat aat cca cat gtt tgt cgt caa


Ala Cys Ala Gly Asn Asn Pro His Val Cys Arg Gln





ggt cgc tgatgctcca ggaccctctg aaccacgacg t


Gly Arg

















TABLE 17








DNA Sequence (SEQ ID NO:90) and Protein Sequence



(SEQ ID NO:91) of S11.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc aat tca gat cgt gat cca gca


Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala





tta ggt ggc agg aat gct gca gcc aaa gcg tct gac


Leu Gly Gly Arg Asn Ala Ala Ala Lys Ala Ser Asp





aag atc gct tcg acc ctc aag aga aga gga tgc tgt


Lys Ile Ala Ser Thr Leu Lys Arg Arg Gly Cys Cys





tcg tat ttt gac tgt aga atg atg ttt cca gaa atg


Ser Tyr Phe Asp Cys Arg Met Met Phe Pro Glu Met





tgt ggt tgg cga ggc tgatgctcca ggaccctctg


Cys Gly Trp Arg Gly





aaccacgacg t

















TABLE 18








DNA Sequence (SEQ ID NO:92) and Protein Sequence



(SEQ ID NO:93) of S11.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc aat tca gat cgt gat cca gca


Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala





tta ggt ggc agg aat gct gca gcc ata gcg tct gac


Leu Gly Gly Arg Asn Ala Ala Ala Ile Ala Ser Asp





aag atc gct tcg acc ctc agg aga gga gga tgc tgt


Lys Ile Ala Ser Thr Leu Arg Arg Gly Gly Cys Cys





tct ttt cct gcc tgt aga aag tat cgt cca gaa atg


Ser Phe Pro Ala Cys Arg Lys Tyr Arg Pro Glu Met





tgt ggt gga cga cgc tgatgctcca ggaccctctg


Cys Gly Gly Arg Arg





aaccacgacg t

















TABLE 19








DNA Sequence (SEQ ID NO:94) and Protein Sequence



(SEQ ID NO:95) of S11.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cat gaa tat gat


Thr Val Val Ser Phe Thr Ser Asp His Glu Ser Asp





agc ggt gat gcc caa acc atc caa gaa gtg ttt gag


Arg Gly Asp Ala Gln Thr Ile Gln Glu Val Phe Glu





atg ttc gct ctg gac agc gat gga tgc tgt tgg cat


Met Phe Ala Leu Asp Ser Asp Gly Cys Cys Trp His





cct gct tgt ggc aga cac tat tgt ggt cga aga cgc


Pro Ala Cys Gly Arg His Tyr Cys Gly Arg Arg Arg





tgatgctcca ggaccctctg aaccacgacg t

















TABLE 20








DNA Sequence (SEQ ID NO:96) and Protein Sequence



(SEQ ID NO:97) of S11.6
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc aat tca gat cgt gat cca gca


Thr Val Val Ser Phe Asn Ser Asp Arg Asp Pro Ala





tta ggt ggc agg aat gct gca gcc ata gcg tct gac


Leu Gly Gly Arg Asn Ala Ala Ala Ile Ala Ser Asp





aag atc gct tcg acc ctc agg aga gga gga tgc tgt


Lys Ile Ala Ser Thr Leu Arg Arg Gly Gly Cys Cys





tct ttt gct gcc tgt aga aag tat cgt cca gaa atg


Ser Phe Ala Ala Cys Arg Lys Tyr Arg Pro Glu Met





tgt ggt gga cga cgc tgatgct


Cys Gly Gly Arg Arg

















TABLE 21








DNA Sequence (SEQ ID NO:98) and Protein Sequence



(SEQ ID NO:99) of S11.7
















atg ttc acc gtg ttt ctg ttg gtt ctc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Leu Leu Ala Thr





acc gtc gtt tcc ttc aat tca gat cgt gca tta ggt


Thr Val Val Ser Phe Asn Ser Asp Arg Ala Leu Gly





ggc agg aat gct gca gcc aaa gcg tct gac aag atc


Gly Arg Asn Ala Ala Ala Lys Ala Ser Asp Lys Ile





ctt tcg aac ctc agg aga gga gga tgc tgt ttt cat


Leu Ser Asn Leu Arg Arg Gly Gly Cys Cys Phe His





cct gtc tgt tac atc aat ctt cta gaa atg tgt cgt


Pro Val Cys Tyr Ile Asn Leu Leu Glu Met Cys Arg





caa cga ggc tgatcgtcca ggaccctctg aaccacgacg t


Gln Arg Gly

















TABLE 22








DNA Sequence (SEQ ID NO:100) and Protein Sequence



(SEQ ID NO:101) of Cn1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr





act gtc gtt tcc ttc cct tca gat agt gca tct gat


Thr Val Val Ser Phe Pro Ser Asp Ser Ala Ser Asp





gtc agg gat gac gaa gcc aaa gac gaa agg tct gac


Val Arg Asp Asp Glu Ala Lys Asp Glu Arg Ser Asp





atg tac aaa tcg aaa cgg aat gga cgc tgt tgc cat


Met Tyr Lys Ser Lys Arg Asn Gly Arg Cys Cys His





cct gcc tgt ggc aaa cac ttt agt tgt gga cgc


Pro Ala Cys Gly Lys His Phe Ser Cys Gly Arg





tgatgctcca ggaccctctg aaccacgacg t

















TABLE 23








DNA Sequence (SEQ ID NO:102) and Protein Sequence



(SEQ ID NO:103) of SmI
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc tcc cct tca gat cgt gca tct gat


Thr Val Val Ser Ser Pro Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc aac gag aaa gcg tct gac


Gly Arg Asn Ala Ala Ala Asn Glu Lys Ala Ser Asp





gtg atc gcg ctg gcc ctc aag gga tgc tgt tcc aac


Val Ile Ala Leu Ala Leu Lys Gly Cys Cys Ser Asn





cct gtc tgt cac ctg gag cat tca aac atg tgt ggt


Pro Val Cys His Leu Glu His Ser Asn Met Cys Gly





aga aga cgc tgatgctcca ggaccctctg aaccacgacg


Arg Arg Arg

















TABLE 24








DNA Sequence (SEQ ID NO:104) and Protein Sequence



(SEQ ID NO:105) of Bt1.1
















atg ttc tcc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Ser Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc tcc act tca ggt ggt gca tct ggt


Thr Val Val Ser Ser Thr Ser Gly Gly Ala Ser Gly





ggc agg aag gct gca gcc aaa gcg tct aac cgg atc


Gly Arg Lys Ala Ala Ala Lys Ala Ser Asn Arg Ile





gct ctg acc gtc agg agt gca aca tgc tgt aat tat


Ala Leu Thr Val Arg Ser Ala Thr Cys Cys Asn Tyr





cct ccc tgt tac gag act tat cca gaa agt tgt ctg


Pro Pro Cys Tyr Glu Thr Tyr Pro Glu Ser Cys Leu





taacgtgaat catccagagc tttgtggctg aagacactga





tgctccagga ccctctgaac cacgacgt

















TABLE 25








DNA Sequence (SEQ ID NO:106) and Protein Sequence



(SEQ ID NO:107) of Bt1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtg gtt tcc ttc act tca ggt cgt gca ttt cgt


Thr Val Val Ser Phe Thr Ser Gly Arg Ala Phe Arg





ggc agg aat cgc gca gcc gac gac aaa agg tct gac


Gly Arg Asn Arg Ala Ala Asp Asp Lys Arg Ser Asp





ctg gcc gct ctg agc gtc agg gga gga tgc tgt tcc


Leu Ala Ala Leu Ser Val Arg Gly Gly Cys Cys Ser





cat cct gcc tgt gcg gtg aat cat cca gag ctt tgt


His Pro Ala Cys Ala Val Asn His Pro Glu Leu Cys





ggc tgaagacgct gatgccccag gaccctctga accacgacgt


Gly

















TABLE 26








DNA Sequence (SEQ ID NO:108) and Protein Sequence



(SEQ ID NO:109) of Bt1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc act tca ggt cgt gca tct ggt


Thr Val Val Ser Phe Thr Ser Gly Arg Ala Ser Gly





ggc agg aat gct gca gcc aaa gcg tct aac cgg atc


Gly Arg Asn Ala Ala Ala Lys Ala Ser Asn Arg Ile





gct atg gcc atc agc agt gga gca tgc tgt gca tat


Ala Met Ala Ile Ser Ser Gly Ala Cys Cys Ala Tyr





cct ccc tgt ttc gag gct tat cca gaa aga tgt ctg


Pro Pro Cys Phe Glu Ala Tyr Pro Glu Arg Cys Leu





taacgtgaat catccagacc tttgtggctg aagacgctga





tgccccagga ccctctgaac cacgacgt

















TABLE 27








DNA Sequence (SEQ ID NO:110) and Protein Sequence



(SEQ ID NO:111) of Bt1.4
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc act tca gat cgt gca ttt cgt


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Phe Arg





ggc agg aat tcc gca gcc aac gac aaa agg tct gac


Gly Arg Asn Ser Ala Ala Asn Asp Lys Arg Ser Asp





ctg gcc gct ctg agc gtc agg aga gga tgc tgc tcc


Leu Ala Ala Leu Ser Val Arg Arg Gly Cys Cys Ser





cat ccc gcc tgt agc gtg aat cat cca gag ctt tgt


His Pro Ala Cys Ser Val Asn His Pro Glu Leu Cys





ggt aga aga cgc tgatgcccca ggaccctctg aaccacgacg t


Gly Arg Arg Arg

















TABLE 28








DNA Sequence (SEQ ID NO:112) and Protein Sequence



(SEQ ID NO:113) of Bt1.5
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc act tca ggt cgt gca tct ggt


Thr Val Val Ser Phe Thr Ser Gly Arg Ala Ser Gly





ggc agg aat gct gca gcc aaa gcg tct aac cgg atc


Gly Arg Asn Ala Ala Ala Lys Ala Ser Asn Arg Ile





gct ctg atc gtc agg aat gca gaa tgc tgt tat tat


Ala Leu Ile Val Arg Asn Ala Glu Cys Cys Tyr Tyr





cct ccc tgt tac gag gct tat cca gaa att tgt ctg


Pro Pro Cys Tyr Glu Ala Tyr Pro Glu Ile Cys Leu





taacgtgaat catccagacc tttgtggctg aagaccctga





tgctccagga ccctctgaac cacgacgt

















TABLE 29








DNA Sequence (SEQ ID NO:114) and Protein Sequence



(SEQ ID NO:115) of Pn1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc att tcc ttc act tca gat cgt gca tat gat


Thr Val Ile Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc ggg aat gcc gca gcg tct gac ctg atc gct ctg


Gly Gly Asn Ala Ala Ala Ser Asp Leu Ile Ala Leu





acc atc aag gga tgc tgt tct cat cct ccc tgt gcc


Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Ala





atg aat aat cca gac tat tgt ggt tgacgacgct


Met Asn Asn Pro Asp Tyr Cys Gly





gatgctccag gaccctctga accacgacg

















TABLE 30








DNA Sequence (SEQ ID NO:116) and Protein Sequence



(SEQ ID NO:117) of Pn1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca tct gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc ggg aat gcc gca atg tct gac ctg atc gct ctg


Gly Gly Asn Ala Ala Met Ser Asp Leu Ile Ala Leu





acc atc aag gga tgc tgt tct cat cct ccc tgt ttc


Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Phe





ctg aat aat cca gac tat tgt ggt tgacgacgct


Leu Asn Asn Pro Asp Tyr Cys Gly





gatgctccag gaccctctga accacgacg

















TABLE 31








DNA Sequence (SEQ ID NO:118) and Protein Sequence



(SEQ ID NO:119) of Sm1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat cgt gaa tct gat


Thr Val Val Ser Phe Pro Ser Asp Arg Glu Ser Asp





ggc gcg aat gac gaa gcc cgc acc gac gag cct gag


Gly Ala Asn Asp Glu Ala Arg Thr Asp Glu Pro Glu





gag cac gga ccg gac agg aat gga tgc tgt agg aat


Glu His Gly Pro Asp Arg Asn Gly Cys Cys Arg Asn





cct gcc tgt gag agc cac aga tgt ggt tgacgacgct


Pro Ala Cys Glu Ser His Arg Cys Gly





gatgctccag gaccctctga accacgacg

















TABLE 32








DNA Sequence (SEQ ID NO:120) and Protein Sequence



(SEQ ID NO:121) of Cr1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat cgt gca tct gat


Thr Val Val Ser Phe Pro Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc agc gac aga gcg tct gac


Gly Arg Asn Ala Ala Ala Ser Asp Arg Ala Ser Asp





gcg gcc cac cag gga tgc tgt tcc aac cct gtc tgt


Ala Ala His Gln Gly Cys Cys Ser Asn Pro Val Cys





cac gtg gaa cat cca gaa ctt tgt cgt aga aga cgc


His Val Glu His Pro Glu Leu Cys Arg Arg Arg Arg





tgatgctcca ggaccctctg aaccacgacg

















TABLE 33








DNA Sequence (SEQ ID NO:122) and Protein Sequence



(SEQ ID NO:123) of Cr1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca aat cgt gaa tct gat


Thr Val Val Ser Phe Pro Ser Asn Arg Glu Ser Asp





ggc gcg aat gcc gaa gtc cgc acc gac gag cct gag


Gly Ala Asn Ala Glu Val Arg Thr Asp Glu Pro Glu





gag cac gac gaa ctg ggc ggg aat gga tgc tgt ggg


Glu His Asp Glu Leu Gly Gly Asn Gly Cys Cys Gly





aat cct gac tgt acg agc cac agt tgt gat tgacgacgct


Asn Pro Asp Cys Thr Ser His Ser Cys Asp





gatgctccag gaccctctga accacgacg

















TABLE 34








DNA Sequence (SEQ ID NO:124) and Protein Sequence



(SEQ ID NO:125) of EpI
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca tct gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





agc agg aag gac gca gcg tct ggc ctg atc gct ctg


Ser Arg Lys Asp Ala Ala Ser Gly Leu Ile Ala Leu





acc atc aag gga tgc tgt tct gat cct cgc tgt aac


Thr Ile Lys Gly Cys Cys Ser Asp Pro Arg Cys Asn





atg aat aat cca gac tat tgt ggt tgacgacgct


Met Asn Asn Pro Asp Tyr Cys Gly





gatgctccag gaccctctga accacgacg

















TABLE 35








DNA Sequence (SEQ ID NO:126) and Protein Sequence



(SEQ ID NO:127) of Sn1.1
















atg tcc acc gtg ttt ctg ttg gtt gtc ctc gca acc



Met Ser Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act gta gat cgt gca tat gat


Thr Val Val Ser Phe Thr Val Asp Arg Ala Ser Asp





ggc agg gat gtc gca atc gac gac aga ttg gtg tat


Gly Arg Asp Val Ala Ile Asp Asp Arg Leu Val Ser





ctc cat cag atc gcc cat gct gac tgt tgt tcc gat


Leu Pro Gln Ile Ala His Ala Asp Cys Cys Ser Asp





cat gcc tgc aag cag acg ccc ggt tgt cgt taaagacgct


Pro Ala Cys Lys Gln Thr Pro Gly Cys Arg





gctgctccag gaccctctga accacgacg

















TABLE 36








DNA Sequence (SEQ ID NO:128) and Protein Sequence



(SEQ ID NO:129) of Sn1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gct tcc ttc att atc gat gat cca tct gat


Thr Val Ala Ser Phe Ile Ile Asp Asp Pro Ser Asp





ggc agg aat att gca gtc gac gac aga ggg ctt ttc


Gly Arg Asn Ile Ala Val Asp Asp Arg Gly Leu Phe





tct acg ctc ttc cat gct gat tgc tgt gaa aat cct


Ser Thr Leu Phe His Ala Asp Cys Cys Glu Asn Pro





gcc tgt aga cac acg cag ggt tgt tgatctttgt


Ala Cys Arg His Thr Gln Gly Cys





tcttcaaaga cactgctggc ccaggaccct ctgaaccacg acg

















TABLE 37








DNA Sequence (SEQ ID NO:130) and Protein Sequence



(SEQ ID NO:131) of Da1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca ttt cgt


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Phe Arg





ggc agg aat gcc gca gcc aaa gag tct ggc ctg gtc


Gly Arg Asn Ala Ala Ala Lys Glu Ser Gly Leu Val





ggt ctg acc gac aag acg cga gga tgc tgt tct cat


Gly Leu Thr Asp Lys Thr Arg Gly Cys Cys Ser His





cct gcc tgt aac gta gat cat cca gaa att tgt ggt


Pro Ala Cys Asn Val Asp His Pro Glu Ile Cys Gly





tgaagacgct gatgctccag gaccctctga accacgacgt

















TABLE 38








DNA Sequence (SEQ ID NO:132) and Protein Sequence



(SEQ ID NO:133) of Da1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat ggt gca tat gat


Thr Val Val Ser Phe Thr Ser Asp Gly Ala Ser Asp





gac agg aaa gcc gct gcg tct gac ctg atc act ctg


Asp Arg Lys Ala Ala Ala Ser Asp Leu Ile Thr Leu





acc atc aag gga tgc tgt tct cgt cct ccc tgt atc


Thr Ile Lys Gly Cys Cys Ser Arg Pro Pro Cys Ile


gcg aat aat cca gac ttg tgt ggt cga cga cgc


Ala Asn Asn Pro Asp Leu Cys Gly Arg Arg Arg





tgatgctcca ggaccctctg

















TABLE 39








DNA Sequence (SEQ ID NO:134) and Protein Sequence



(SEQ ID NO:135) of Da1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc tcc act tca ggt cgt cgt gca ttt


Thr Val Val Ser Ser Thr Ser Gly Arg Arg Ala Phe





cat ggc agg aat gcc gca gcc aaa gcg tct gga ctg


His Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc ggt ctg act gac agg aga cca caa tgc tgt agt


Val Gly Leu Thr Asp Arg Arg Pro Gln Cys Cys Ser





gat cct cgc tgt aac gta ggt cat cca gaa ctt tgt


Asp Pro Arg Cys Asn Val Gly His Pro Glu Leu Cys





ggt gga aga cgc tgatgctcca ggaccctctg aaccacaacg t


Gly Gly Arg Arg

















TABLE 40








DNA Sequence (SEQ ID NO:136) and Protein Sequence



(SEQ ID NO:137) of Da1.4
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc tcc act tca ggt cgt gca ttt cat


Thr Val Val Ser Ser Thr Ser Gly Arg Ala Phe His





ggc agg aat gcc gca gcc aaa gcg tct ggc ctg gtc


Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu Val





ggt ctg acc gac aag agg caa gta tgc tgt agt gat


Gly Leu Thr Asp Lys Arg Gln Val Cys Cys Ser Asp





cct cgc tgt aac gta ggt cat cca gaa att tgt ggt


Pro Arg Cys Asn Val Gly His Pro Glu Ile Cys Gly





gga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Gly Arg Arg

















TABLE 41








DNA Sequence (SEQ ID NO:138) and Protein Sequence



(SEQ ID NO:139) of A1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr





act gtc gtt tcc ttc cct tca gat agt gca tct ggt


Thr Val Val Ser Phe Pro Ser Asp Ser Ala Ser Gly





ggc agg gat gac gag gcc aaa gac gaa agg tct gac


Gly Arg Asp Asp Glu Ala Lys Asp Glu Arg Ser Asp





atg tac gaa ttg aaa cgg aat gga cgc tgt tgc cat


Met Tyr Glu Leu Lys Arg Asn Gly Arg Cys Cys His





cct gcc tgt ggt ggc aaa tac gtt aaa tgt gga cgc


Pro Ala Cys Gly Gly Lys Tyr Val Lys Cys Gly Arg





tgatgctcca ggaccctctc gaaccacg

















TABLE 42








DNA Sequence (SEQ ID NO:140) and Protein Sequence



(SEQ ID NO:141) of Bu1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc tct aca gat gat gaa tct gat


Thr Val Val Ser Phe Ser Thr Asp Asp Glu Ser Asp





ggc tcg aat gaa gaa ccc agc gcc gac cag act gcc


Gly Ser Asn Glu Glu Pro Ser Ala Asp Gln Thr Ala





agg tcc tca atg aac agg gcg cct gga tgc tgt aac


Arg Ser Ser Met Asn Arg Ala Pro Gly Cys Cys Asn





aat cct gcc tgt gtg aag cac aga tgt gga tgacgctgat


Asn Pro Ala Cys Val Lys His Arg Cys Gly





gctccaggac cctctgaacc acgacgt

















TABLE 43








DNA Sequence (SEQ ID NO:142) and Protein Sequence



(SEQ ID NO:143) of Bu1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc tct aca gat gat gaa tct gat


Thr Val Val Ser Phe Ser Thr Asp Asp Glu Ser Asp





ggc tcg aat gaa gaa ccc agc gcc gac cag gct gcc


Gly Ser Asn Glu Glu Pro Ser Ala Asp Gln Ala Ala





agg tcc gca atg aac agg ccg cct gga tgc tgt aac


Arg Ser Ala Met Asn Arg Pro Pro Gly Cys Cys Asn





aat cct gcc tgt gtg aag cac aga tgt ggt gga


Asn Pro Ala Cys Val Lys His Arg Cys Gly Gly





tgacgctgat gctccaggac cctctgaacc acgacgt

















TABLE 44








DNA Sequence (SEQ ID NO:144) and Protein Sequence



(SEQ ID NO:145) of Bu1.3
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat cgt gac tct gat


Thr Val Val Ser Phe Pro Ser Asp Arg Asp Ser Asp





ggc gcg gat gcc gaa gcc agt gac gag cct gtt gag


Gly Ala Asp Ala Glu Ala Ser Asp Glu Pro Val Glu





ttc gaa agg gac gag aat gga tgc tgt tgg aat cct


Phe Glu Arg Asp Glu Asn Gly Cys Cys Trp Asn Pro





tcc tgt ccg agg ccc aga tgt aca gga cga cgc


Ser Cys Pro Arg Pro Arg Cys Thr Gly Arg Arg





taatgctcca ggaccctctg aaccacgacg t

















TABLE 45








DNA Sequence (SEQ ID NO:146) and Protein Sequence



(SEQ ID NO:170) of Bu1.4
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg aca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Thr Thr





act gtc gtt tcc ttc cct tca gat cgt gca tct gat


Thr Val Val Ser Phe Pro Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc aac gac aaa gcg tct gac


Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala Ser Asp





gtg gtc acg ctg gtc ctc aag gga tgc tgt tcc acc


Val Val Thr Leu Val Leu Lys Gly Cys Cys Ser Thr





cct ccc tgt gct gtg ctg tat tgt ggt aga aga cgc


Pro Pro Cys Ala Val Leu Tyr Cys Gly Arg Arg Arg





tgatgctcca ggaccctctg aaccacgacg t

















TABLE 46








DNA Sequence (SEQ ID NO:148) and Protein Sequence



(SEQ ID NO:149) of Di1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttc gca tcc



Met Phe Thr Val Phe Leu Leu Val Val Phe Ala Ser





tat gtc acc tta gat cgt gca tat tat ggc agg tat


Ser Val Thr Leu Asp Arg Ala Ser Tyr Gly Arg Tyr





gcc tca ccc gtc gac aga gcg tct gcc ctg atc gct


Ala Ser Pro Val Asp Arg Ala Ser Ala Leu Ile Ala





cag gcc atc ctt cga gat tgc tgc tcc aat cct cct


Gln Ala Ilc Leu Arg Asp Cys Cys Ser Asn Pro Pro





tgt gcc cat aat aat cca gac tgt cgt taaagacgct


Cys Ala His Asn Asn Pro Asp Cys Arg





gcttgctcca ggaccctctg aaccacgacg t

















TABLE 47








DNA Sequence (SEQ ID NO:150) and Protein Sequence



(SEQ ID NO:151) of T1
















gga tga tgt tat aat act acc tgt atc gag aag aat



Gly Cys Cys Ser Asn Pro Pro Cys Ile Ala Lys Asn





aca cac atg tgt ggt gga aga aga tga


Pro His Met Cys Gly Gly Arg Arg

















TABLE 48








DNA Sequence (SEQ ID NO:152) and Protein Sequence



(SEQ ID NO:153) of Cn1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc ttc cct tca gat cgt gca tct gat


Thr Val Val Ser Phe Pro Ser Asp Arg Ala Ser Asp





ggc agg aat gcc gca gcc aac gac aaa gcg tct gac


Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala Ser Asp





gtg atc acg ctg gcc ctc aag gga tgc tgt tcc aac


Val Ile Thr Leu Ala Leu Lys Gly Cys Cys Ser Asn





cct gtc tgt cac ttg gag cat tca aac ctt tgt ggt


Pro Val Cys His Leu Glu His Ser Asn Leu Cys Gly





aga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Arg Arg Arg

















TABLE 49








DNA Sequence (SEQ ID NO:233) and Protein Sequence



(SEQ ID NO:234) of Im1.1
















tat gat gga aag agt gcc gag gcc aaa gcc aaa cag



Ser Asp Gly Lys Ser Ala Ala Ala Lys Ala Lys Pro





tat cac ctg acg gct cca ttc atc agg gac gaa tgc


Ser His Leu Thr Ala Pro Phe Ile Arg Asp Glu Cys





tgt tcc gat tat agc tgt ggc aag aac tgt ctt tga


Cys Ser Asp Ser Arg Cys Gly Lys Asn Cys Leu

















TABLE 50








DNA Sequence (SEQ ID NO:235) and Protein Sequence



(SEQ ID NO:236) of Im1.2
















ttt gat gga agg aat gcc cca gcc gac gac aaa gcg



Phe Asp Gly Arg Asn Ala Pro Ala Asp Asp Lys Ala





tct gac ctg atc gct caa atc gtc agg aga gca tgc


Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Ala Cys





tgt tcc gat cgt cgc tgt aga tgg agg tgt ggt tga


Cys Ser Asp Arg Arg Cys Arg Trp Arg Cys Gly

















TABLE 51








DNA Sequence (SEQ ID NO:237) and Protein Sequence



(SEQ ID NO:238) of Rg1.2
















tat gat gga agg aat gcc gca gcc gac gcc aga gag



Ser Asp Gly Arg Asn Ala Ala Ala Asp Ala Arg Ala





tat acc cgg atc gct att tta atc agg tta aaa tga


Ser Pro Arg Ile Ala Leu Phe Leu Arg Phe Thr Cys





tgt agg aga ggt aaa tgt tca cag aaa tgt ggt


Cys Arg Arg Gly Thr Cys Ser Gln His Cys Gly





tgaagaaaat gatgataaag gaaaatatga aaaaagaagt

















TABLE 52








DNA Sequence (SEQ ID NO:239) and Protein Sequence



(SEQ ID NO:240) of Rg1.6
















tat aat gga agg aat gcc gca gcc gac gcc aaa gag



Ser Asn Gly Arg Asn Ala Ala Ala Asp Ala Lys Ala





tat caa cgg atc gct aaa tta atc agg gac tat tgc


Ser Gln Arg Ile Ala Pro Phe Leu Arg Asp Tyr Cys





tgt agg aga cat gcc tgt acg ttg att tgt ggt


Cys Arg Arg His Ala Cys Thr Leu Ile Cys Gly





tgaagacgct gctgctccag gaccctctga accacgacgt

















TABLE 53








DNA Sequence (SEQ ID NO:241) and Protein Sequence



(SEQ ID NO:242) of Rg1.6A
















tat aat gga agg aat gcc gca gcc gac gcc aaa gcg



Ser Asn Gly Arg Asn Ala Ala Ala Asp Ala Lys Ala





tct caa cgg atc gct cca ttc ctc agg gac tat tgc


Ser Gln Arg Ile Ala Pro Phe Leu Arg Asp Tyr Cys





tgt agg aga cct ccc tgt acg ttg att tgt ggt


Cys Arg Arg Pro Pro Cys Thr Leu Ile Cys Gly





tgaagacgct gctgctccag gaccctctga accacgacgt

















TABLE 54








DNA Sequence (SEQ ID NO:243) and Protein Sequence



(SEQ ID NO:244) of Rg1.7
















tat aat aaa agg aag aat gcc gca atg ctt gac atg



Ser Asn Lys Arg Lys Asn Ala Ala Met Leu Asp Met





atc gct caa cac gcc ata agg ggt tgc tgt tcc gat


Ile Ala Gln His Ala Ile Arg Gly Cys Cys Ser Asp





cct cgc tgt aga tat aga tgt cgt tgaagacgct


Pro Arg Cys Arg Tyr Arg Cys Arg





gctgctccag gaccctctga accacgacgt

















TABLE 55








DNA Sequence (SEQ ID NO:245) and Protein Sequence



(SEQ ID NO:246) of Rg1.9
















ttt aat gga agg agt gcc gca gcc gac caa aat gag



Phe Asn Gly Arg Ser Ala Ala Ala Asp Gln Asn Ala





cat ggc ctg atc gct caa gtc gtc aga gga ggg tgc


Pro Gly Leu Ile Ala Gln Val Val Arg Gly Gly Cys





tgt tcc gat ccc cgc tgc gcc tgg aga tgt ggt


Cys Ser Asp Pro Arg Cys Ala Trp Arg Cys Gly





tgaagacgtt gctgctccag gaccctctga accacgacgt

















TABLE 56








DNA Sequence (SEQ ID NO:247) and Protein Sequence



(SEQ ID NO:248) of Rg1.10
















ttt gat gga agg aat gcc gca gcc gac gcc aaa gtg



Phe Asp Gly Arg Asn Ala Ala Ala Asp Ala Lys Val





att aac acg gtc gct cga atc gcc tgg gat ata tgc


Ile Asn Thr Val Ala Arg Ile Ala Trp Asp Ile Cys





tgt tcc gaa cct gac tgt aac cat aaa tgt gtt


Cys Ser Glu Pro Asp Cys Asn His Lys Cys Val





tgaagacgct tctgctccag gaccctctga accacgacgt

















TABLE 57








DNA Sequence (SEQ ID NO:249) and Protein Sequence



(SEQ ID NO:250) of Rg1.11
















tat aat aaa agg aag aat gcc gca atg ctt gac atg



Ser Asn Lys Arg Lys Asn Ala Ala Met Leu Asp Met





atc gct caa cac gcc ata agg ggt tgc tgt tcc gat


Ile Ala Gln His Ala Ile Arg Gly Cys Cys Ser Asp





cct cgc tgt aaa cat cag tgt ggt tgaagacgct


Pro Arg Cys Lys His Gln Cys Gly





gctgctccag gaccctctga accacgacgt

















TABLE 58








DNA Sequence (SEQ ID NO:251) and Protein Sequence



(SEQ ID NO:252) of Ms1.7
















atc aag aat aca gca gcc agc aac aaa gcg tct agc



Ile Lys Asn Thr Ala Ala Ser Asn Lys Ala Ser Ser





ctg gtg gct ctt gtt gtc agg gga tgc tgt tac aat


Leu Val Ala Leu Val Val Arg Gly Cys Cys Tyr Asn





cct gtc tgc aag aaa tat tat tgt tgg aaa ggc


Pro Val Cys Lys Lys Tyr Tyr Cys Trp Lys Gly





tgatgctcca ggaccctctg aaccacgacg t

















TABLE 59








DNA Sequence (SEQ ID NO:253) and Protein Sequence



(SEQ ID NO:254) of P1.7
















tat gaa ggc agg aat gct gaa gcc atc gac aac gcc



Ser Glu Gly Arg Asn Ala Glu Ala Ile Asp Asn Ala





tta gac cag agg gat cca aag cga cag gag ccg ggg


Leu Asp Gln Arg Asp Pro Lys Arg Gln Glu Pro Gly





tgc tgt agg cat cct gcc tgt ggg aag aac aga tgt


Cys Cys Arg His Pro Ala Cys Gly Lys Asn Arg Cys





gga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Gly Arg Arg

















TABLE 60








DNA Sequence (SEQ ID NO:255) and Protein Sequence



(SEQ ID NO:256) of Ms1.2
















tat gat ggc agg aat att gca gtc gac gac aga tgg



Ser Asp Gly Arg Asn Ile Ala Val Asp Asp Arg Trp





tat ttc tat acg ctc ttc cat gct act tgc tgt gcc


Ser Phe Tyr Thr Leu Phe His Ala Thr Cys Cys Ala





gat cct gac tgt aga ttc cgg ccc ggt tgt tgatctttgt


Asp Pro Asp Cys Arg Phe Arg Pro Gly Cys





tcttcaaaga cgctgctggc ccaggaccct ctgaaccacg acgt

















TABLE 61








DNA Sequence (SEQ ID NO:257) and Protein Sequence



(SEQ ID NO:258) of Ms1.3
















atc aag aat act gca gcc agc aac aaa gcg cct agc



Ile Lys Asn Thr Ala Ala Ser Asn Lys Ala Pro Ser





ctg gtg gct att gcc gtc agg gga tgc tgt tac aat


Leu Val Ala Ile Ala Val Arg Gly Cys Cys Tyr Asn





cct tcc tgt tgg ccg aaa aca tat tgt agt tggaaaggct


Pro Ser Cys Trp Pro Lys Thr Tyr Cys Ser





gatgctccag gaccctctga accacgacgt

















TABLE 62








DNA Sequence (SEQ ID NO:259) and Protein Sequence



(SEQ ID NO:260) of Ms1.4
















tat gat agc agg aat gtc gca atc gag gac aga gtg



Ser Asp Ser Arg Asn Val Ala Ile Glu Asp Arg Val





tat gac ctg cac tct atg ttc ttc gat gtt tct tgc


Ser Asp Leu His Ser Met Phe Phe Asp Val Ser Cys





tgt agc aat cct acc tgt aaa gaa acg tat ggt tgt


Cys Ser Asn Pro Thr Cys Lys Glu Thr Tyr Gly Cys





tgatcgttgg ttttgaagac gctgatgctc caggaccctc

















TABLE 63








DNA Sequence (SEQ ID NO:261) and Protein Sequence



(SEQ ID NO:262) of Ms1.5
















tat gtt ggc agg aat att gca gtc gac gac aga ggg



Ser Val Gly Arg Asn Ile Ala Val Asp Asp Arg Gly





att ttc tat acg ctc ttc cat gct cat tgc tgt gcc


Ile Phe Ser Thr Leu Phe His Ala His Cys Cys Ala





aat ccc atc tgt aaa aac acg ccc ggt tgt tgatctttgt


Asn Pro Ile Cys Lys Asn Thr Pro Gly Cys





tcttcaaaga cgctgctggc ccaggaccct ctgaaccacg acgt

















TABLE 64








DNA Sequence (SEQ ID NO:263) and Protein Sequence



(SEQ ID NO:264) of Ms1.8
















tcc gat ggc agg aat gtc gca atc gac gac aga gtg



Ser Asp Gly Arg Asn Val Ala Ile Asp Asp Arg Val





tat gac ctg cac tat atg ttc ttc gat att gct tgc


Ser Asp Leu His Ser Met Phe Phe Asp Ile Ala Cys





tgt aac aat cat acc tgt aaa gaa acg tat ggt tgt


Cys Asn Asn Pro Thr Cys Lys Glu Thr Tyr Gly Cys





tgatcgttgg ttttgaagac gctgatgctc caggaccctc





tgaaccacga cgt

















TABLE 65








DNA Sequence (SEQ ID NO:265) and Protein Sequence



(SEQ ID NO:266) of Ms1.9
















tat gat ggc agg aat gtc gca atc gag gac aga gtg



Ser Asp Gly Arg Asn Val Ala Ile Glu Asp Arg Val





tat gac ctg ctc tat atg ctc ttc gat gtt gct tgc


Ser Asp Leu Leu Ser Met Leu Phe Asp Val Ala Cys





tgt agc aat cct gtc tgt aaa gaa acg tat ggt tgt


Cys Ser Asn Pro Val Cys Lys Glu Thr Tyr Gly Cys





tgatcgttgg ttttgaagac gctgatgctc caggaccctc





tgaaccacga cgt

















TABLE 66








DNA Sequence (SEQ ID NO:267) and Protein Sequence



(SEQ ID NO:268) of Bt1.7
















tat gat ggc agg aat gct gcc gcc gac gac aaa gct



Tyr Asp Gly Arg Asn Ala Ala Ala Asp Asp Lys Ala





ttt gac ctg ctg gct atg acc ata agg gga gga tgc


Phe Asp Leu Leu Ala Met Thr Ile Arg Gly Gly Cys





tgt tcc tat cct ccc tgt atc gcg agt aat cct aaa


Cys Ser Tyr Pro Pro Cys Ile Ala Ser Asn Pro Lys





tgt ggt gga aga cgc tgatgctcca ggaccctctg


Cys Gly Gly Arg Arg





aaccacaacg t

















TABLE 67








DNA Sequence (SEQ ID NO:269) and Protein Sequence



(SEQ ID NO:270) of Lv1.5
















ttt gat ggc agg aat gct gca ggc aac gcc aaa atg



Phe Asp Gly Arg Asn Ala Ala Gly Asn Ala Lys Met





tcc gcc ctg atg gcc ctg acc atc agg gga tgc tgt


Ser Ala Leu Met Ala Leu Thr Ile Arg Gly Cys Cys





tcc cat cct gtc tgt agc gcg atg agt cca atc tgt


Ser His Pro Val Cys Ser Ala Met Ser Pro Ile Cys





ggc tgaagacgct gatgccccag gaccctctga accacgacgt


Gly

















TABLE 68








DNA Sequence (SEQ ID NO:271) and Protein Sequence



(SEQ ID NO:272) of Ms1.10
















atc aag aat gct gca gct gac gac aaa gca tct gac



Ile Lys Asn Ala Ala Ala Asp Asp Lys Ala Ser Asp





ctg ctc tct cag atc gtc agg aat gct gca tcc aat


Leu Leu Ser Gln Ile Val Arg Asn Ala Ala Ser Asn





gac aaa ggg tct gac ctg atg act ctt gcc ctc agg


Asp Lys Gly Ser Asp Leu Met Thr Leu Ala Leu Arg





gga tgc tgt aaa aat cct tac tgt ggt gcg tcg aaa


Gly Cys Cys Lys Asn Pro Tyr Cys Gly Ala Ser Lys





aca tat tgt ggt aga aga cgc tgatgctcca ggaccctctg


Thr Tyr Cys Gly Arg Arg Arg





aaccacgacg t

















TABLE 69








DNA Sequence (SEQ ID NO:273) and Protein Sequence



(SEQ ID NO:274) of Om1.1
















tctgatggca ggaatgccgc agcgtctgac ctgatggat ctg



                                           Leu





acc atc aag gga tgc tgt tct tat cct ccc tgt ttc


Thr Ile Lys Gly Cys Cys Ser Tyr Pro Pro Cys Phe





gcg act aat cca gac tgt ggt cga cga cgc tgatgctcca


Ala Thr Asn Pro Asp Cys Gly Arg Arg Arg





ggaccctctg aaccacgacg t

















TABLE 70








DNA Sequence (SEQ ID NO:275) and Protein Sequence



(SEQ ID NO:276) of R1.6
















ttt gat ggc agg aat gcc gca gcc gac tac aaa ggg



Phe Asp Gly Arg Asn Ala Ala Ala Asp Tyr Lys Gly





tct gaa ttg ctc gct atg acc gtc agg gga gga tgc


Ser Glu Leu Leu Ala Met Thr Val Arg Gly Gly Cys





tgt tcc tat cct ccc tgt atc gca aat aat cct ctt


Cys Ser Tyr Pro Pro Cys Ile Ala Asn Asn Pro Leu





tgt gct gga aga cgc tga


Cys Ala Gly Arg Arg

















TABLE 71








DNA Sequence (SEQ ID NO:277) and Protein Sequence



(SEQ ID NO:278) of R1.7
















ttt gat ggc agg aat gcc gca gcc gac tac aaa ggg



Phe Asp Gly Arg Asn Ala Ala Ala Asp Tyr Lys Gly





tct gaa ttg ctc gct atg acc gtc agg gga gga tgc


Ser Glu Leu Leu Ala Met Thr Val Arg Gly Gly Cys





tgt tcc tat cct ccc tgt atc gca aat aat cct ttt


Cys Ser Tyr Pro Pro Cys Ile Ala Asn Asn Pro Phe





tgt gct gga aga cgc tga


Cys Ala Gly Arg Arg

















TABLE 72








DNA Sequence (SEQ ID NO:279) and Protein Sequence



(SEQ ID NO:280) of Vr1.1
















tat tat gac agg tat gcc tag acc gtc gac aga gag



Ser Tyr Asp Arg Tyr Ala Ser Pro Val Asp Arg Ala





tat gcc ctg atc gct cag gcc atc ctt cga gat tgc


Ser Ala Leu Ile Ala Gln Ala Ile Leu Arg Asp Cys





tgt tcc aat cat ccc tgt tcc caa aat aat cca gac


Cys Ser Asn Pro Pro Cys Ser Gln Asn Asn Pro Asp





tgt atg taaagacgct gcttgctcca ggaccctctg


Cys Met





aaccacgacg t

















TABLE 73








DNA Sequence (SEQ ID NO:281) and Protein Sequence



(SEQ ID NO:282) of Vr1.2
















tat tat ggc agg tat gcc tca ccc gtc gac aga gcg



Ser Tyr Gly Arg Tyr Ala Ser Pro Val Asp Arg Ala





tct gcc ctg atc gct cag gcc atc ctt cga gat tgc


Ser Ala Leu Ile Ala Gln Ala Ile Leu Arg Asp Cys





tgc tcc aat cct cct tgt gcc cat aat aat cca gac


Cys Ser Asn Pro Pro Cys Ala His Asn Asn Pro Asp





tgt cgt taaagacgct gcttgctcca ggaccctctg


Cys Arg





aaccacgacg t

















TABLE 74








DNA Sequence (SEQ ID NO:283) and Protein Sequence



(SEQ ID NO:284) of A1.4
















tat gat ggc agg aat gcc gca gcc aac gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala





tct ggc atg agc gcg ctg gcc gtc aat gaa tgc tgt


Ser Gly Met Ser Ala Leu Ala Val Asn Glu Cys Cys





acc aac cct gtc tgt cac gcg gaa cat caa gaa ctt


Thr Asn Pro Val Cys His Ala Glu His Gln Glu Leu





tgt gct aga aga cgc tga


Cys Ala Arg Arg Arg

















TABLE 75








DNA Sequence (SEQ ID NO:285) and Protein Sequence



(SEQ ID NO:286) of A1.5
















tat gat ggc agg aat gcc gca gcc aac gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala





tct gac gtg atc acg ctg gcc ctc aag gga tgc tgt


Ser Asp Val Ile Thr Leu Ala Leu Lys Gly Cys Cys





tcc aac cct gtc tgt cac ttg gag cat tca aac ctt


Ser Asn Pro Val Cys His Leu Glu His Ser Asn Leu





tgt ggt aga aga cgc tga


Cys Gly Arg Arg Arg

















TABLE 76








DNA Sequence (SEQ ID NO:287) and Protein Sequence



(SEQ ID NO:288) of A1.6
















tat gat ggc agg aat gcc gca gcc aac gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala





tct ggc atg agc gcg ctg gcc gtc aat gaa tgc tgt


Ser Gly Met Ser Ala Leu Ala Val Asn Glu Cys Cys





acc aac cct gtc tgt cac gtg gaa cat caa gaa ctt


Thr Asn Pro Val Cys His Val Glu His Gln Glu Leu





tgt gct aga aga cgc tga


Cys Ala Arg Arg Arg

















TABLE 77








DNA Sequence (SEQ ID NO:289) and Protein Sequence



(SEQ ID NO:290) of Af1.1
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca ttt cgt


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Phe Arg





ggc agg aat gcc gca gcc aaa gcg tct ggc ctg gtc


Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu Val





ggt ctg acc gac aag agg caa gaa tgc tgt tct tat


Gly Leu Thr Asp Lys Arg Gln Glu Cys Cys Ser Tyr





cct gcc tgt aac cta gat cat cca gaa ctt tgt ggt


Pro Ala Cys Asn Leu Asp His Pro Glu Leu Cys Gly





tgaagacgct gatgctccag gaccctctga accacgacgt

















TABLE 78








DNA Sequence (SEQ ID NO:291) and Protein Sequence



(SEQ ID NO:292) of Af1.2
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





act gtc gtt tcc tcc act tca ggt cgt cgt gca ttt


Thr Val Val Ser Ser Thr Ser Gly Arg Arg Ala Phe





cgt ggc agg aat gcc gca gcc aaa gcg tct gga ctg


Arg Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly Leu





gtc ggt ctg act gac agg aga cca gaa tgc tgt agt


Val Gly Leu Thr Asp Arg Arg Pro Glu Cys Cys Ser





gat act agc tgt aaa tag act cat aca gaa att tgt


Asp Pro Arg Cys Asn Ser Thr His Pro Glu Leu Cys





ggt gga aga agc tgatgataaa ggaaaatatg aaaaaagaag t


Gly Gly Arg Arg

















TABLE 79








DNA Sequence (SEQ ID NO:293) and Protein Sequence



(SEQ ID NO:294) of Ar1.2
















tat gat ggc agg aat gcc gca gcc aac gcg ttt gac



Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp





ctg atc gat ctg acc gcc agg cta aat tgc tgt atg


Leu Ile Asp Leu Thr Ala Arg Leu Asn Cys Cys Met





att ccc ccc tgt tgg aag aaa tat gga gac aga tgt


Ile Pro Pro Cys Trp Lys Lys Tyr Gly Asp Arg Cys





agt gaa gta cgc tgatgctcca ggaccctctg aaccacgacg t


Ser Glu Val Arg

















TABLE 80








DNA Sequence (SEQ ID NO:295) and Protein Sequence



(SEQ ID NO:296) of Ar1.3
















tat gat ggc agg aat gcc gca agc aaa gcg ttt ggc



Ser Asp Gly Arg Asn Ala Ala Arg Lys Ala Phe Gly





tgc tgc gac tta ata ccc tgt ttg gag aga tat ggt


Cys Cys Asp Leu Ile Pro Cys Leu Glu Arg Tyr Gly





aac aga tgt aat gaa gtg cac tgatgctcca ggaccctctg


Asn Arg Cys Asn Glu Val His





aaccacgcga cgt

















TABLE 81








DNA Sequence (SEQ ID NO:297) and Protein Sequence



(SEQ ID NO:298) of Ar1.4
















tat gat ggc agc aat gcc gca gcc aac gag ttt gac



Ser Asp Gly Ser Asn Ala Ala Ala Asn Glu Phe Asp





ctg atc gct ctg acc gcc agg cta ggt tgc tgt aac


Leu Ile Ala Leu Thr Ala Arg Leu Gly Cys Cys Asn





gtt aca ccc tgt tgg gag aaa tat gga gac aaa tgt


Val Thr Pro Cys Trp Glu Lys Tyr Gly Asp Lys Cys





aat gaa gta cgc tgatgcttca ggaccctctg aaccacgacg T


Asn Glu Val Arg

















TABLE 82








DNA Sequence (SEQ ID NO:299) and Protein Sequence



(SEQ ID NO:300) of Ar1.5
















tat gat ggc agg aat gtc gca gca aaa gag ttt cac



Ser Asp Gly Arg Asn Val Ala Ala Lys Ala Phe His





cgg atc ggc cgg acc atc agg gat gaa tgc tgt tcc


Arg Ile Gly Arg Thr Ile Arg Asp Glu Cys Cys Ser





aat cat gcc tgt agg gtg aat aat cca cac gtt tgt


Asn Pro Ala Cys Arg Val Asn Asn Pro His Val Cys





aga cga cgc tgatgctcca ggaccctctg aaccacgacg t


Arg Arg Arg

















TABLE 83








DNA Sequence (SEQ ID NO:301) and Protein Sequence



(SEQ ID NO:302) of Ar1.6
















tat gat ggc agg aat gcc gca gcc aac gcg ttt gac



Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Phe Asp





ctg atg cct ctg acc gcc agg cta aat tgc tgt agc


Leu Met Pro Leu Thr Ala Arg Leu Asn Cys Cys Ser





att ccc ggc tgt tgg aac gaa tat aaa gac aga tgt


Ile Pro Gly Cys Trp Asn Glu Tyr Lys Asp Arg Cys





agt aaa gta cgc tgatgctcca ggaccctctg aaccacgacg T


Ser Lys Val Arg

















TABLE 84








DNA Sequence (SEQ ID NO:303) and Protein Sequence



(SEQ ID NO:304) of Ay1.2















tctgatggca ggaatgccgc agccgacgac aaagcgtctg






acctggtcgc t ctg gtc gtc agg gga gga tgc tgt tcc


             Leu Val Val Arg Gly Gly Cys Cys Ser





cac cat gtc tgt tac ttt aat aat cca caa atg tgt


His Pro Val Cys Tyr Phe Asn Asn Pro Gln Met Cys





agt gga aga agc tgatgataaa ggaaaatatg aaccacgacg t


Arg Gly Arg Arg

















TABLE 85








DNA Sequence (SEQ ID NO:305) and Protein Sequence



(SEQ ID NO:306) of Ay1.3
















tctgatggca ggaatgccgc agccgacgac aaagcgtctg






acctggtcgc t ctg gcc gtc agg gga gga tgc tgt tcc


             Leu Ala Val Arg Gly Gly Cys Cys Ser





cac cat gtc tgt aac ttg aat aat cca caa atg tgt


His Pro Val Cys Asn Leu Asn Asn Pro Gln Met Cys





agt gga aga agc tgatgataaa ggaaaatatg aaccacgacg t


Arg Gly Arg Arg

















TABLE 86








DNA Sequence (SEQ ID NO:307) and Protein Sequence



(SEQ ID NO:308) of Bt1.8
















ttt cgt ggc agg aat ccc gca gcc aac gac aaa agg



Phe Arg Gly Arg Asn Pro Ala Ala Asn Asp Lys Arg





tat gac ctg gcc gct ctg agc gtc agg gga gga tgc


Ser Asp Leu Ala Ala Leu Ser Val Arg Gly Gly Cys





tgt tcc cat cct gcc tgt agc gtg act cat cca gag


Cys Ser His Pro Ala Cys Ser Val Thr His Pro Glu





ctt tgt ggc tgaagacgct gatgccccag gaccctctga


Leu Cys Gly





accacgacgt

















TABLE 87








DNA Sequence (SEQ ID NO:309) and Protein Sequence



(SEQ ID NO:310) of Bt1.9
















tat gat ggc ggg aat gcc gca gcc aaa gcg tct gac



Ser Asp Gly Gly Asn Ala Ala Ala Lys Ala Ser Asp





ctg atc gct cag acc atc agg gga gga tgc tgt tcc


Leu Ile Ala Gln Thr Ile Arg Gly Gly Cys Cys Ser





tat cct gcc tgt agc gtg gaa cat caa gac ctt tgt


Tyr Pro Ala Cys Ser Val Glu His Gln Asp Leu Cys





gat gga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Asp Gly Arg Arg

















TABLE 88








DNA Sequence (SEQ ID NO:311) and Protein Sequence



(SEQ ID NO:312) of Ca1.3
















tat tat ggc agg aat gcc gca gcc aaa gcg ttt gaa



Ser Tyr Gly Arg Asn Ala Ala Ala Lys Ala Phe Glu





gtg agt tgc tgt gtc gtt agc ccc tgt tgg att agc


Val Ser Cys Cys Val Val Arg Pro Cys Trp Ile Arg





tat caa gag gaa tgt ctt gaa gca gat ccc agg acc


Tyr Gln Glu Glu Cys Leu Glu Ala Asp Pro Arg Thr





ctc tga


Leu

















TABLE 89








DNA Sequence (SEQ ID NO:313) and Protein Sequence



(SEQ ID NO:314) of Ca1.4
















tat gat ggc agg aat gcc gca gcc aac gcc ctt gac



Ser Asp Gly Arg Asn Ala Ala Ala Asn Ala Leu Asp





ctg atc act ctg atc gcc agg caa aat tgc tgt agc


Leu Ile Thr Leu Ile Ala Arg Gln Asn Cys Cys Ser





att ccc ggc tgt tgg gag aaa tat gga gac aaa tgt


Ile Pro Gly Cys Trp Glu Lys Tyr Gly Asp Lys Cys





agt gaa gta cgc tga


Ser Glu Val Arg

















TABLE 90








DNA Sequence (SEQ ID NO:315) and Protein Sequence



(SEQ ID NO:316) of C1.2
















tat gat gga agg aat gaa gaa gcc aaa gac gaa gag



Ser Asp Gly Arg Asn Glu Ala Ala Asn Asp Glu Ala





tat gaa gtg ata gag atg gaa ata aag gga tga tgt


Ser Asp Val Ile Glu Leu Ala Leu Lys Gly Cys Cys





taa aaa aat gta tgt aaa ttg gag cat cca aac gct


Ser Asn Pro Val Cys His Leu Glu His Pro Asn Ala





tgt ggt aga aga agc tgatgctcca ggaccctctg


Cys Gly Arg Arg Arg





aaccacgacg t

















TABLE 91








DNA Sequence (SEQ ID NO:317) and Protein Sequence



(SEQ ID NO:318) of C1.3
















tat gat ggc agg aat gcc gca gcc aac gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala





tct gac ctg gtc gct ctg gcc gtc agg gga tgc tgt


Ser Asp Leu Val Ala Leu Ala Val Arg Gly Cys Cys





tcc aac cct atc tgt tac ttt aat aat cca cga att


Ser Asn Pro Ile Cys Tyr Phe Asn Asn Pro Arg Ile





tgt cgt gga aga cgc tgatgctcca ggaccctctg


Cys Arg Gly Arg Arg





aaccacgacg t

















TABLE 92








DNA Sequence (SEQ ID NO:319) and Protein Sequence



(SEQ ID NO:320) of Ep1.2
















tat cat ggc agg aat gcc gca agc aaa gcg tct gac



Ser His Gly Arg Asn Ala Ala Arg Lys Ala Ser Asp





ctg atc gct ctg aaa gtc agg gaa tga tgt tat cag


Leu Ile Ala Leu Thr Val Arg Glu Cys Cys Ser Gln





cat aaa tgt agc tgg aaa cat aaa gaa att tgt agt


Pro Pro Cys Arg Trp Lys His Pro Glu Leu Cys Ser





tga

















TABLE 93








DNA Sequence (SEQ ID NO:321) and Protein Sequence



(SEQ ID NO:322) of G1.1
















tat gat gga agg aat gac gaa gcc aaa gag ttt gac



Ser Asp Gly Arg Asn Asp Ala Ala Lys Ala Phe Asp





atg ata tat tag aaa gta aag aaa gga tga tgt taa


Leu Ile Ser Ser Thr Val Lys Lys Gly Cys Cys Ser





aat aat gaa tgt gag ggg aat aat aaa aat att tgt


His Pro Ala Cys Ala Gly Asn Asn Gln His Ile Cys





gga aga aga aga tgatgataaa ggaaaatatg aaaaaagaag t


Gly Arg Arg Arg

















TABLE 94








DNA Sequence (SEQ ID NO:323) and Protein Sequence



(SEQ ID NO:324) of G1.3
















tat gat ggc agg aat gcc gca gcc aac gac caa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Gln Ala





tct gac ctg atg gct gag acc gtc agg gga tgc tgt


Ser Asp Leu Met Ala Ala Thr Val Arg Gly Cys Cys





gcc gtt cct tcc tgt cgc ctc cgt aat cca gac ctt


Ala Val Pro Ser Cys Arg Leu Arg Asn Pro Asp Leu





tgt ggt gga gga agc tgatgctcca ggaccctctg


Cys Gly Gly Gly Arg





aaccacgacg t

















TABLE 95








DNA Sequence (SEQ ID NO:325) and Protein Sequence



(SEQ ID NO:326) of Im1.3
















ctt gat gaa agg aat gcc gca gcc gac gac aaa gcg



Leu Asp Glu Arg Asn Ala Ala Ala Asp Asp Lys Ala





tct gac ctg atc gct caa atc gtc agg aga gga tgc


Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Gly Cys





tgt tcc cat cct gcc tgt aac gtg aat aat cca cac


Cys Ser His Pro Ala Cys Asn Val Asn Asn Pro His





att tgt ggt tga


Ile Cys Gly

















TABLE 96








DNA Sequence (SEQ ID NO:327) and Protein Sequence



(SEQ ID NO:328) of Lv1.2
















tat gat gga agg aat act gaa gcc aaa gtc aaa tat



Ser Asp Gly Arg Asn Thr Ala Ala Lys Val Lys Tyr





tat aag acg cag gag gaa tgc tgt acc aat cat acc


Ser Lys Thr Pro Glu Glu Cys Cys Pro Asn Pro Pro





tgt tta gag aca aat tag gat att tgt gga gga aga


Cys Phe Ala Thr Asn Ser Asp Ile Cys Gly Gly Arg





aga tgatgataaa ggaaaatatg aaaaaagaag t


Arg

















TABLE 97








DNA Sequence (SEQ ID NO:329) and Protein Sequence



(SEQ ID NO:330) of Lv1.3
















tat aat ggc agg aat gcc gca gcc aaa ttc aaa gcg



Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala





cct gcc ctg atg aag cgg acc gtc agg gat gct tgc


Pro Ala Leu Met Lys Arg Thr Val Arg Asp Ala Cys





tgt tca gac cct cgc tgt tcc ggg aaa cat caa gac


Cys Ser Asp Pro Arg Cys Ser Gly Lys His Gln Asp





ctg tgt ggc tgaagacgct gatgctccag gaccctctga


Leu Cys Gly





accacgacgt

















TABLE 98








DNA Sequence (SEQ ID NO:331) and Protein Sequence



(SEQ ID NO:332) of Lv1.4
















tat aat ggc agg aat gcc gca gcc aaa ttc aaa gcg



Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala





cct gcc ctg atg gag ctg acc gtc agg gaa gat tgc


Pro Ala Leu Met Glu Leu Thr Val Arg Glu Asp Cys





tgt tca gac cct cgc tgt tcc gtg gga cat caa gac


Cys Ser Asp Pro Arg Cys Ser Val Gly His Gln Asp





ctg tgt ggc tgaagacgct gatgctccag gaccctctga


Leu Cys Gly





Accacgacgt

















TABLE 99








DNA Sequence (SEQ ID NO:333) and Protein Sequence



(SEQ ID NO:334) of Lv1.6
















gca ttt gat ggc agg aat gct gca gcc agc gac aaa



Ala Phe Asp Gly Arg Asn Ala Ala Ala Ser Asp Lys





gag tcc gag ctg atg gct ctg gcc gtc agg gga tgc


Ala Ser Glu Leu Met Ala Leu Ala Val Arg Gly Cys





tgt tcc cat cct gcc tgt gct ggg agt aat gca cat


Cys Ser His Pro Ala Cys Ala Gly Ser Asn Ala His





atc tgt ggc aga aga cgc tgatgctcca ggaccctctg


Ile Cys Gly Arg Arg Arg





aaccacgacg t

















TABLE 100








DNA Sequence (SEQ ID NO:335) and Protein Sequence



(SEQ ID NO:336) of Lv1.7
















tat aat ggc agg aat gcc gca gcc aaa ttc aaa gcg



Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala





cct gcc ctg atg aag ctg acc gtc agg gag gat tgc


Pro Ala Leu Met Lys Leu Thr Val Arg Glu Asp Cys





tgt tca gac cct cgc tgt tcc gtg gga cat caa gac


Cys Ser Asp Pro Arg Cys Ser Val Gly His Gln Asp





atg tgt ggc tgaagacgct gatgctccag gaccctctga


Met Cys Gly





atcacgacgt

















TABLE 101








DNA Sequence (SEQ ID NO:337) and Protein Sequence



(SEQ ID NO:338) of Lv1.8
















ttt gaa tgc agg aat gct gca ggc aac gac aaa gag



Phe Glu Cys Arg Asn Ala Ala Gly Asn Asp Lys Ala





act gac ctg atg gct ctg act gtc agg gga tgc tgt


Thr Asp Leu Met Ala Leu Thr Val Arg Gly Cys Cys





tcc cat cat gcc tgt gct ggg aat aat cca cat atc


Ser His Pro Ala Cys Ala Gly Asn Asn Pro His Ile





tgc ggc tgaagacgct gatgctccag gaccctctga


Cys Gly





accacgacgt

















TABLE 102








DNA Sequence (SEQ ID NO:339) and Protein Sequence



(SEQ ID NO:340) of Lv1.9
















ttt gat ggc agg aac gcc gca gcc aac aac aaa gag



Phe Asp Gly Arg Asn Ala Ala Ala Asn Asn Lys Ala





act gat ctg atg gct ctg act gtc aga gga tgc tgt


Thr Asp Leu Met Ala Lau Thr Val Arg Gly Cys Cys





ggc aat cct tca tgt agc atc cat att cct tac gtt


Gly Asn Pro Sar Cys Sar Ile His Ile Pro Tyr Val





tgt aat tagagacact gatgctccag gaccctctga


Cys Asn





accacgacgt

















TABLE 103








DNA Sequence (SEQ ID NO:341) and Protein Sequence



(SEQ ID NO:342) of Lv1.10
















tat aat ggc agg aat gcc gca gcc aaa ttc aaa gcg



Ser Asn Gly Arg Asn Ala Ala Ala Lys Phe Lys Ala





cct gcc ctg atg aag cgg acc gac agc gaa gaa tgc


Pro Ala Leu Met Lys Arg Thr Asp Ser Glu Glu Cys





tgt tta gac tct cgc tgt gcc ggg caa cat caa gac


Cys Leu Asp Ser Arg Cys Ala Gly Gln His Gln Asp





ctg tgt ggc gga aga cgc tgatgctcca ggaccctctg


Leu Cys Gly Gly Arg Arg





aaccacgacg t

















TABLE 104








DNA Sequence (SEQ ID NO:343) and Protein Sequence



(SEQ ID NO:344) of Mr1.3
















tat gat ggc agg aat gcc gca gcc aag gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala





tct gac ctg gtc gct ctg acc gtc aag gga tgc tgt


Ser Asp Leu Val Ala Leu Thr Val Lys Gly Cys Cys





tct aat cct ccc tgt tac gcg aat aat caa gcc tat


Ser Asn Pro Pro Cys Tyr Ala Asn Asn Gln Ala Tyr





tgt aat gga aga cgc tga


Cys Asn Gly Arg Arg

















TABLE 105








DNA Sequence (SEQ ID NO:345) and Protein Sequence



(SEQ ID NO:346) of Mr1.4
















tat gat ggc agg aat gcc gca gcc aag gac aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ala Lys Asp Lys Ala





tct gac ctg gtc gct ctg acc gtc aag gga tgc tgt


Ser Asp Leu Val Ala Leu Thr Val Lys Gly Cys Cys





tct cat cct gcc tgt agc gtg aat aat cca gac att


Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile





tgt ggt tga


Cys Gly

















TABLE 106








DNA Sequence (SEQ ID NO:347) and Protein Sequence



(SEQ ID NO:348) of Ms1.1
















tat gat ggc agg aat gct gca gcc aac aac aaa gtg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asn Lys Val





gct ttg acc atg agg gga aaa tga tgt atc aat gat


Ala Leu Thr Met Arg Gly Lys Cys Cys Ile Asn Asp





gag tgt agc tag aaa cat cca cag taa tgt tat gga


Ala Cys Arg Ser Lys His Pro Gln Tyr Cys Ser Gly





aga agc tgataataaa ggaaaatatg aaaaaagaag t


Arg Arg

















TABLE 107








DNA Sequence (SEQ ID NO:349) and Protein Sequence



(SEQ ID NO:350) of Ms1.6
















tat gat ggc agg aat gct gca gcc aac gac aaa gtg



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Val





tct gac cag atg gct ctg gtt gtc agg gga tgc tgt


Ser Asp Gln Met Ala Leu Val Val Arg Gly Cys Cys





tac aat att gcc tgt aga att aat aat cca cgg tac


Tyr Asn Ile Ala Cys Arg Ile Asn Asn Pro Arg Tyr





tgt cgt gga aaa cgc tgatgttcca ggaccctctg


Cys Arg Gly Lys Arg





aaccacgacg t

















TABLE 108








DNA Sequence (SEQ ID NO:351) and Protein Sequence



(SEQ ID NO:352) of O1.1
















tctgaaggca ggaatgccgc agccaacgac aaagcgtctg






acctgatggc t ctg aac gtc agg gga tgc tgt tcc cat


             Leu Asn Val Arg Gly Cys Cys Ser His





cat gtc tgt agc tta aat tat cca aaa tat tgt ggt


Pro Val Cys Arg Phe Asn Tyr Pro Lys Tyr Cys Gly





gga aga agc tgatggtaaa ggaaaatatg aaccacgacg t


Gly Arg Arg

















TABLE 109








DNA Sequence (SEQ ID NO:353) and Protein Sequence



(SEQ ID NO:354) of O1.2
















tctgatggcg ggaatgccgc agcaaaagcg tttgatctaa tcact






ctg gcc ctc agg gat gaa tgc tgt gcc agt cct ccc


Leu Ala Leu Arg Asp Glu Cys Cys Ala Ser Pro Pro





tgt cgt ttg aat aat cca tac gta tgt cat tgacgacgct


Cys Arg Leu Asn Asn Pro Tyr Val Cys His





gatgctccag gaccctctga accacgacgt

















TABLE 110








DNA Sequence (SEQ ID NO:355) and Protein Sequence



(SEQ ID NO:356) of O1.4
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc acc act tca gat agt gca tat gat


Thr Val Val Ser Pro Thr Sar Asp Arg Ala Sar Asp





agg agg aat gcc gca gcc aaa gag ttt gaa atg aga


Arg Arg Asn Ala Ala Ala Lys Ala Phe Asp Leu Arg





tat tag aaa gcc aag aga gga tga tgt tca aat cat


Tyr Ser Thr Ala Lys Arg Gly Cys Cys Ser Asn Pro





gtc tgt tgg cag aat aat gaa gaa taa tgt agt gaa


Val Cys Trp Gln Asn Asn Ala Glu Tyr Cys Arg Glu





agt gga taatgataaa ggaaaatatg aaaaaagaag t


Ser Gly

















TABLE 111








DNA Sequence (SEQ ID NO:357) and Protein Sequence



(SEQ ID NO:358) of O1.7
















atg ttc acc gtg ttt ctg ttg gtt gtc ttg gca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ala Thr





acc gtc gtt tcc ttc act tca gat cgt gca tat gat


Thr Val Val Ser Phe Thr Ser Asp Arg Ala Ser Asp





ggc ggg aat gtc gca gag tat cac ctg atc gct ctg


Gly Gly Asn Val Ala Ala Ser His Leu Ile Ala Leu





acc atc aag gga tgc tgt tat cac cat ccc tgt gcc


Thr Ile Lys Gly Cys Cys Ser His Pro Pro Cys Ala





cag aat aat caa gac tat tgt ggt tgacgacgct


Gln Asn Asn Gln Asp Tyr Cys Gly





gatgctccag gaccctctga accacgacgt

















TABLE 112








DNA Sequence (SEQ ID NO:3 59) and Protein Sequence



(SEQ ID NO:360) of O1.8
















atg ttc acc gtg ttt ctg ttg gtt gtc tta tca acc



Met Phe Thr Val Phe Leu Leu Val Val Leu Ser Thr





acc gtc gtt tcc tcc act tca gat cgt gca tct gat


Thr Val Val Ser Ser Thr Ser Asp Arg Ala Ser Asp





agg agg aat gcc gca gcc aaa gcg tct gac ctg atg


Arg Arg Asn Ala Ala Ala Lys Ala Ser Asp Leu Met





tat tcg acc gtc aag aaa gga tgt tgt tcc cat cct


Tyr Ser Thr Val Lys Lys Gly Cys Cys Ser His Pro





gcc tgt tcg ggg aat aat cga gaa tat tgt cgt gaa


Ala Cys Ser Gly Asn Asn Arg Glu Tyr Cys Arg Glu





agt ggc taatgctcca ggaccctctg aaccacgacg t


Ser Gly

















TABLE 113








DNA Sequence (SEQ ID NO:361) and Protein Sequence



(SEQ ID NO:362) of Om1.2
















tttgatggaa ggaatgaata agcagacaga aaagtggatg






acaggataga t cag atc gac agg gat aca tga tgt tca


             Gln Ile Asp Arg Asp Pro Cys Cys Ser





tat cat gac tgt ggc gag aat cat cca gag att tgt


Tyr Pro Asp Cys Gly Ala Asn His Pro Glu Ile Cys





ggt gga aaa agc tgatgataaa ggaaaatatg aaaaaagaag t


Gly Gly Lys Arg

















TABLE 114








DNA Sequence (SEQ ID NO:363) and Protein Sequence



(SEQ ID NO:364) of Om1.3
















tctcatggca ggaatgccgc acgct ctg acc gtc agg gaa



                            Leu Thr Val Arg Glu





tgc tgt tat cag cat cat tgt agc tgg aaa cat cca


Cys Cys Ser Gln Pro Pro Cys Arg Trp Lys His Pro





gaa att tgt agt tgaagaagat gatgataaag gaaaatatga


Glu Leu Cys Ser





aaaaagaagt

















TABLE 115








DNA Sequence (SEQ ID NO:365) and Protein Sequence



(SEQ ID NO:366) of Om1.4
















tttgatggca ggaatgctgc agccagcgac aaagcgtctg






agctgatggc t ctg gcc gtc agg gga tgc tgt tcc cat


             Leu Ala Val Arg Gly Cys Cys Ser His





cat gcc tgt gct ggg aat aat cca cat atc tgt ggc


Pro Ala Cys Ala Gly Asn Asn Pro His Ile Cys Gly





aga aga cgc tgatgctcca ggaccctctg aaccacgacg t


Arg Arg Arg

















TABLE 116








DNA Sequence (SEQ ID NO:367) and Protein Sequence



(SEQ ID NO:368) of Om1.5
















tctggtgtca ggaaagacgc agcgcctggc ctgatcgct ctg acc



                                           Leu Thr





atc aag gga tgc tgt tct gat cct agc tgt aac gtg


Ile Lys Gly Cys Cys Ser Asp Pro Ser Cys Asn Val





aat aat cca gac tat tgt ggt tgacgacgct gatgctccag


Asn Asn Pro Asp Tyr Cys Gly





gaccctctga accacgacgt

















TABLE 117








DNA Sequence (SEQ ID NO:369) and Protein Sequence



(SEQ ID NO:370) of Om1.6
















tctaatggca ggaatgccgc agccaaattc aaagcgcctg






ccctgatgga g ctg acc gtc agg gaa gaa tgc tgt tca


             Leu Thr Val Arg Glu Glu Cys Cys Ser





gac cat agc tgt tcc gtg gga cat caa gat atg tgt


Asp Pro Arg Cys Ser Val Gly His Gln Asp Met Cys





cgg tgaagcacgt gatgctccag gaccctctga accacgacgt


Arg

















TABLE 118








DNA Sequence (SEQ ID NO:371) and Protein Sequence



(SEQ ID NO:372) of P1.4
















act gat ggc agg aat gct gca gcc ata gcg ctt gac



Thr Asp Gly Arg Asn Ala Ala Ala Ile Ala Leu Asp





ctg atc gct ccg gcc gtc agg gga gga tgc tgt tcc


Leu Ile Ala Pro Ala Val Arg Gly Gly Cys Cys Ser





aat cct gcc tgt tta gtg aat cat cta gaa atg tgt


Asn Pro Ala Cys Leu Val Asn His Leu Glu Met Cys





ggt aaa aga cgc tgatgcccca ggaccctctg aaccacgacg t


Gly Lys Arg Arg

















TABLE 119








DNA Sequence (SEQ ID NO:373) and Protein Sequence



(SEQ ID NO:374) of P1.5
















tat gat ggc agg gat gcc gca gcc aac gac aaa gcg



Ser Asp Gly Arg Asp Ala Ala Ala Asn Asp Lys Ala





tct gac ctg atc gct ctg acc gcc agg aga gat cca


Ser Asp Leu Ile Ala Leu Thr Ala Arg Arg Asp Pro





tgc tgt ttc aat cct gcc tgt aac gtg aat aat cca


Cys Cys Phe Asn Pro Ala Cys Asn Val Asn Asn Pro





cag att tgt ggt tgaagacgct gatgctccag gaccctctga


Gln Ile Cys Gly





accacgacgt

















TABLE 120








DNA Sequence (SEQ ID NO:375) and Protein Sequence



(SEQ ID NO:376) of P1.6
















tat gat ggc agg gat gct gag aaa aca ggc ttt gac



Ser Asp Gly Arg Asp Ala Glu Lys Thr Gly Phe Asp





acg acc att gtg ccg gaa gac tgc tgt tcg gat cct


Thr Thr Ile Val Pro Glu Asp Cys Cys Ser Asp Pro





tcc tgt tgg agg ctg cat agt tta gct tgt act gga


Ser Cys Trp Arg Leu His Ser Leu Ala Cys Thr Gly





att gta aac cgc tgatgctcca ggaccctctg aaccacgacg t


Ile Val Asn Arg

















TABLE 121








DNA Sequence (SEQ ID NO:377) and Protein Sequence



(SEQ ID NO:378) of P1.8
















act gat ggc agg agt gct gca gcc ata gcg ttt gcc



Thr Asp Gly Arg Ser Ala Ala Ala Ile Ala Phe Ala





ctg atc gct ccg acc gtc tcc tgt act aat cct gcc


Leu Ile Ala Pro Thr Val Cys Cys Thr Asn Pro Ala





tgt ctc gtg aat aat ata cgc ttt tgt ggt gga aga


Cys Leu Val Asn Asn Ile Arg Phe Cys Gly Gly Arg





cgc tgatgcccca ggaccctctg aaccacgacg t


Arg

















TABLE 122








DNA Sequence (SEQ ID NO:379) and Protein Sequence



(SEQ ID NO:380) of Rg1.1
















tat gat gga aga aat gcc gca agc gac gcc aaa gcg



Ser Asp Gly Arg Asn Ala Ala Ser Asp Ala Lys Ala





ttt ccc cgg atc gct cca atc gtc agg gac gaa tgc


Phe Pro Arg Ile Ala Pro Ile Val Arg Asp Glu Cys





tgt agc gat cct agg tgt cac ggg aat aat cgg gac


Cys Ser Asp Pro Arg Cys His Gly Asn Asn Arg Asp





cac tgt gct tgaagacgct gctgctccag gaccctctga


His Cys Ala





accacgacgt

















TABLE 123








DNA Sequence (SEQ ID NO:381) and Protein Sequence



(SEQ ID NO:382) of Rg1.3
















tat gat ggc agg aat acc gag gcc gac gaa aaa gag



Ser Asp Gly Arg Asn Thr Ala Ala Asp Glu Lys Ala





tcc gac ctg atc tat caa act gtc aag aga gat tgc


Ser Asp Leu Ile Ser Gln Thr Val Lys Arg Asp Cys





tgt tcc cat cat cta tgt aga tta ttt gtt cca gga


Cys Ser His Pro Leu Cys Arg Leu Phe Val Pro Gly





ctt tgt att tgaagacgct gctgctccag gaccctctga


Leu Cys Ile





Accacgact

















TABLE 124








DNA Sequence (SEQ ID NO:383) and Protein Sequence



(SEQ ID NO:384) of Rg1.4
















tat gat ggc agg aat gcc gca gcc gac aac aaa gag



Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Lys Ala





tat gac cta atc gct caa atc gtc agg aga gga tgc


Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Gly Cys





tgt tcc cat cat gtc tgt aaa gtg agg tat cca gac


Cys Ser His Pro Val Cys Lys Val Arg Tyr Pro Asp





ctg tgt cgt tgaagacgct gctgctccag gaccctctga


Leu Cys Arg





Accacgacgt

















TABLE 125








DNA Sequence (SEQ ID NO:385) and Protein Sequence



(SEQ ID NO:386) of Rg1.5
















tat gat ggc agg aat gcc gca gcc gac aac aga gag



Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Arg Ala





tat gac cta atc gct caa atc gtc agg aga gga tgc


Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Gly Cys





tgt tcc cat cat gcc tgt aat gtg aat aat cca cac


Cys Ser His Pro Ala Cys Asn Val Asn Asn Pro His





att tgt ggt tgaagacgct gctgctccag gaccctctga


Ile Cys Gly





accacgacgt

















TABLE 126








DNA Sequence (SEQ ID NO:387) and Protein Sequence



(SEQ ID NO:388) of Rg1.8
















tat gat ggc agg aat gcc gca gcc gac aac aaa ccg



Ser Asp Gly Arg Asn Ala Ala Ala Asp Asn Lys Pro





tat gac cta atc gct caa atc gtc agg aga gga tgc


Ser Asp Leu Ile Ala Gln Ile Val Arg Arg Gly Cys





tgt tcg cat cct gtc tgt aaa gtg agg tat tca gac


Cys Ser His Pro Val Cys Lys Val Arg Tyr Ser Asp





atg tgt ggt tgaagacgct gctgctccag gaccctctga


Met Cys Gly





accacgacgt

















TABLE 127








DNA Sequence (SEQ ID NO:389) and Protein Sequence



(SEQ ID NO:390) of Sm1.4
















tat gat gga agg aat gaa gag aga aga aaa agc gtc



Ser Asp Gly Arg Asn Ala Glu Arg Arg Gln Ser Val





tgt cat ggt agc tat gga aaa agg gga gga tgt tgt


Cys Pro Gly Arg Ser Gly Pro Arg Gly Gly Cys Cys





taa aaa aat gaa tgt aag gtg aat ttt aaa aaa agt


Ser His Pro Ala Cys Lys Val His Phe Pro His Ser





tgt ggt tgaagaagat gatgataaag gaaaatatga


Cys Gly





aaaaagaagt

















TABLE 128








DNA Sequence (SEQ ID NO:391) and Protein Sequence



(SEQ ID NO:392) of Sm1.5
















tat gat ggc agg aat gcc gca gcc agc gac aga gag



Ser Asp Gly Arg Asn Ala Ala Ala Ser Asp Arg Ala





tat gac gag gcc cac cag gta tgc tgt tcc aac cat


Ser Asp Ala Ala His Gln Val Cys Cys Ser Asn Pro





gtc tgt cac gtg gat cat cca gaa ctt tgt cgt aga


Val Cys His Val Asp His Pro Glu Leu Cys Arg Arg





aga agc tgatgctcca ggaccctctg aaccacgacg t


Arg Arg

















TABLE 129








DNA Sequence (SEQ ID NO:393) and Protein Sequence



(SEQ ID NO:394) of S1.5
















tat gat ggc agg aat gcc gag gcc aac gac aaa gag



Ser Asp Gly Arg Asn Ala Ala Ala Asn Asp Lys Ala





tat gac ctg gtc gct cag gcc atc agg gga tgc tgt


Ser Asp Leu Val Ala Pro Ala Ile Arg Gly Cys Cys





tcc cac cat gtc tgt aac ttg agt aat cca caa att


Ser His Pro Val Cys Asn Leu Ser Asn Pro Gln Ile





tgt cgt gga aga agc tgatgctcca ggaccctctg


Cys Arg Gly Arg Arg





aaccacgacg t

















TABLE 130








DNA Sequence (SEQ ID NO:395) and Protein Sequence



(SEQ ID NO:396) of Tx1.5
















ttt cat ggc agg aat gcc gca gcc aaa gcg tct ggc



Phe His Gly Arg Asn Ala Ala Ala Lys Ala Ser Gly





ctg gtc ggt ctg acc gac aag agg caa gaa tgc tgt


Leu Val Gly Leu Thr Asp Lys Arg Gln Glu Cys Cys





tct cat cct gcc tgt aac gta gat cat cca gaa att


Ser His Pro Ala Cys Asn Val Asp His Pro Glu Ile





tgt cgt tga


Cys Arg

















TABLE 131








DNA Sequence (SEQ ID NO:397) and Protein Sequence



(SEQ ID NO:398) of T1.1
















act gat ggc agg agt gct gca gcc ata gcg ttt gcc



Thr Asp Gly Arg Ser Ala Ala Ala Ile Ala Phe Ala





ctg atc gct ccg acc gtc tgg gaa gga tgc tgt tct


Leu Ile Ala Pro Thr Val Trp Glu Gly Cys Cys Ser





aat cct gcc tgt ctc gtg aat cat ata cgc ttt tgt


Asn Pro Ala Cys Leu Val Asn His Ile Arg Phe Cys





ggt gga aga cgc tgatgcccca ggaccctctg aaccacgacg t


Gly Gly Arg Arg

















TABLE 132








DNA Sequence (SEQ ID NO:399) and Protein Sequence



(SEQ ID NO:400) of Vr1.3
















tat aat ggc atg aat gcc gca gcc atc agg aaa gcg



Ser Asn Gly Met Asn Ala Ala Ala Ile Arg Lys Ala





tct gcc ctg gtg gct cag atc gcc cat cga gac tgc


Ser Ala Leu Val Ala Gln Ile Ala His Arg Asp Cys





tgt gac gat cct gcc tgc acc gtg aat aat cca ggc


Cys Asp Asp Pro Ala Cys Thr Val Asn Asn Pro Gly





ctt tgc act tgaagatgct gctgccccag gaccctctga


Leu Cys Thr





accacgacgt

















TABLE 133








DNA Sequence (SEQ ID NO:401) and Protein Sequence



(SEQ ID NO:402) of G1.2
















tat gat ggc ggg aat gcc gca gca aaa gag tat gac



Ser Asp Gly Gly Asn Ala Ala Ala Lys Glu Ser Asp





gtg atc gct ctg acc gtc tgg aaa tgc tgt acc att


Val Ile Ala Leu Thr Val Trp Lys Cys Cys Thr Ile





cct tcc tgt tat gag aaa aaa aaa att aaa gca tgt


Pro Ser Cys Tyr Glu Lys Lys Lys Ile Lys Ala Cys





gtc ttt tgacgacgct gatgctccag gaccctctga


Val Phe





accacgacgt

















TABLE 134








DNA Sequence (SEQ ID NO:403) and Protein Sequence



(SEQ ID NO:404) of Rg1.12
















tat gat ggc gca gtc gac gac aaa gag ttg gat cga



Ser Asp Gly Ala Val Asp Asp Lys Ala Leu Asp Arg





atc gct gaa atc gtc agg aga gga tgc tgt ggc aat


Ile Ala Glu Ile Val Arg Arg Gly Cys Cys Gly Asn





cat gcc tgt agc ggc tcc tag aaa gat gca ccc tat


Pro Ala Cys Ser Gly Ser Ser Lys Asp Ala Pro Ser





tgt ggt tgaagacgct gctgctccag gaccctctga


Cys Gly





accacgacgt









It will be appreciated that the methods and compositions of the instant invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent to the artisan that other embodiments exist and do not depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.


BIBLIOGRAPHY



  • Barnay, G. et al. (2000). J. Med. Chem.

  • Bitan, G. et al. (1997). J. Peptide Res. 49:421-426.

  • Blount, K. et al. (1992). Toxicon 30:835-842.

  • Bodansky et al. (1966). Chem. Ind. 38: 1597-98.

  • Cartier, G. E. et al. (1996). J. Biol. Chem. 271:7522-7528.

  • Cruz, L. J. at al. (1976). Verliger 18:302-308.

  • Cruz, L. J. et al. (1987). J. Biol. Chem. 260:9280-9288.

  • Fainzilber, M. et al. (1994). Biochemistry 33:9523-9529.

  • Gray, W. R. et al. (1981). J. Biol. Chem. 256:4734-4740.

  • Haack, J. A. et al. (1990). J. Biol. Chem. 265:6025-6029.

  • Horiki, K. et al. (1978). Chemistry Letters 165-68.

  • Hubry, V. et al. (1994). Reactive Polymers 22:231-241.

  • Jacobsen, R. et al. (1997). J. Biol. Chem. 272:22531-22537.

  • Johnson, D. S. et al. (1995). Mol. Pharmacol. 48:194-199.

  • Kapoor (1970). J. Pharm. Sci. 59:1-27.

  • Kornreich, W. D. et al. (1986). U.S. Pat. No. 4,569,967.

  • Luo, S. et al. (1998). J. Neurosci. 18:8571-8679.

  • Marshall, I. G. and Harvey, A. L. (1990). Toxicon 28:231-234.

  • Martinez, J. S. et al. (1995). Biochem. 34:14519-14526.

  • McIntosh, J. M. et al. (1982). Arch. Biochem. Biophys. 218:329-334.

  • Mena, E. E. et al. (1990). Neurosci. Lett. 118:241-244.


  • Methoden der Organischen Chemie (Houben-Weyl): Synthese von Peptiden, E. Wunsch (Ed.), Georg Thieme Verlag, Stuttgart, Ger. (1974).

  • Myers, R. A. et al. (1991). Biochemistry 30:9370-9377.

  • Nishiuchi, Y. et al. (1993). Int. J. Pept. Protein Res. 42:533-538.

  • Nowak, L. et al. (1984). Nature 307:462-465.

  • Olivera, B. M. et al. (1984). U.S. Pat. No. 4,447,356.

  • Olivera, B. M. et al. (1985). Science 230:1338-1343.

  • Olivera, B. M. et al. (1996). U.S. Pat. No. 5,514,774.

  • Rivier, J. R. et al. (1978). Biopolymers 17:1927-38.

  • Rivier, J. R. et al. (1987). Biochem. 26:8508-8512.

  • Sambrook, J. et al. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

  • Schroder & Lubke (1965). The Peptides 1:72-75, Academic Press, NY.

  • Shon, K.-J. et al. (1994). Biochemistry 33:11420-11425.

  • Stewart and Young, Solid-Phase Peptide Synthesis, Freeman & Co., San Francisco, Calif. (1969).

  • Vale et al. (1978). U.S. Pat. No. 4,105,603.

  • Van de Steen, P. et al. (1998). Critical Rev. in Biochem. and Mol. Biol. 33:151-208.

  • Zafaralla, G. C. et al. (1988). Biochemistry 27:7102-7105.

  • Zhou L. M., et al. (1996). J. Neurochem. 66:620-628.

  • U.S. Pat. No. 3,972,859.

  • U.S. Pat. No. 3,842,067.

  • U.S. Pat. No. 3,862,925.

  • U.S. Pat. No. 5,550,050.

  • PCT Published Application WO 92/19195.

  • PCT Published Application WO 94/25503.

  • PCT Published Application WO 95/01203.

  • PCT Published Application WO 95/05452.

  • PCT Published Application WO 96/02286.

  • PCT Published Application WO 96/02646.

  • PCT Published Application WO 96/11698.

  • PCT Published Application WO 96/40871.

  • PCT Published Application WO 96/40959.

  • PCT Published Application WO 97/12635.


Claims
  • 1. An isolated α-conotoxin peptide of generic formula I (SEQ ID NO:1) selected from the group consisting of:
  • 2. The isolated α-conotoxin peptide of claim 1, wherein Xaa1 is Glu.
  • 3. The isolated α-conotoxin peptide of claim 1, wherein Xaa2 is Lys.
  • 4. The isolated α-conotoxin peptide of claim 1, wherein Xaa4 is Tyr.
  • 5. The isolated α-conotoxin peptide of claim 1, wherein Xaa4 is mono-iodo-Tyr.
  • 6. The isolated α-conotoxin peptide of claim 1, wherein Xaa4 is di-iodo-Tyr.
  • 7. The isolated α-conotoxin peptide of claim 1, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 8. An isolated α-conotoxin peptide having the generic formula II: Xaa1-Xaa2-Xaa3-Xaa4-Cys-Cys-Xaa5-Xaa6-Xaa7-Xaa8-Cys-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Cys-Xaa15-Xaa16-Xaa17 (SEQ ID NO:2), wherein Xaa1 is des-Xaa1, Asp, Glu or γ-carboxy-Glu (Gla); Xaa2 is des-Xaa2, Gln, Ala, Asp, Glu, Gla; Xaa3 is des-Xaa3, Gly, Ala, Asp, Glu, Gla, Pro or hydroxy-Pro; Xaa4 is des-Xaa4, Gly, Glu, Gla, Gln, Asp, Asn, Pro or hydroxy-Pro; Xaa5 is Ser, Thr, Gly, Glu, Gla, Asn, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa6 is Asp, Asn, His, halo-His, Thr, Ser, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa7 is Pro or hydroxy-Pro; Xaa8 is Ala, Ser, Thr, Asp, Val, Ile, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa9 is Gly, Ile, Leu, Val, Ala, Thr, Ser, Pro, hydroxy-Pro, Phe, Trp (D or L), neo-Trp, halo-Trp, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid or any unnatural aromatic amino acid; Xaa10 is Ala, Asn, Phe, Pro, hydroxy-Pro, Glu, Gla, Gln, His, halo-His, Val, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa11 is Thr, Ser, His, halo-His, Leu, Ile, Val, Asn, Met, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa12 is Asn, Pro, hydroxy-Pro, Gln, Ser, Thr, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa13 is des-Xaa13, Gly, Thr, Ser, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa14 is des-Xaa14, Ile, Val, Asp, Leu, Phe, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; and Xaa15 is des-Xaa15, Gly, Ala, Met, Ser, Thr, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa16 is des-Xaa16, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa17 is des-Xaa17, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; and the C-terminus contains a free carboxyl group or an amide group.
  • 9. An isolated α-conotoxin peptide of the generic formula II (SEQ ID NO:2) of claim 8 selected from the group consisting of:
  • 10. The isolated α-conotoxin peptide of claim 9, wherein Xaa2 is Lys.
  • 11. The isolated α-conotoxin peptide of claim 9, wherein Xaa1 is Glu.
  • 12. The isolated α-conotoxin peptide of claim 9, wherein Xaa3 is Trp.
  • 13. The isolated re α-conotoxin peptide of claim 9, wherein Xaa4 is Tyr.
  • 14. The isolated α-conotoxin peptide of claim 9, wherein Xaa4 is mono-iodo-Tyr.
  • 15. The isolated α-conotoxin peptide of claim 9, wherein Xaa4 is di-iodo-Tyr.
  • 16. The isolated α-conotoxin peptide of claim 8, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 17. The isolated α-conotoxin peptide of claim 9, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 18. An isolated α-conotoxin peptide having the generic formula III: Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Cys-Cys-Xaa6-Xaa7-Xaa8-Xaa9-Cys-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Cys-Xaa17-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24 (SEQ ID NO:3), wherein Xaa1 is des-Xaa1, Ser or Thr; Xaa2 is des-Xaa2, Asp, Glu, γ-carboxy-Glu (Gla), Asn, Ser or Thr; Xaa3 is des-Xaa3, Ala, Gly, Asn, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa4 is des-Xaa4, Ala, Val, Leu, Ile, Gly, Glu, Gla, Gln, Asp, Asn, Phe, Pro, hydroxy-Pro or any unnatural aromatic amino acid; Xaa5 is des-Xaa5, Thr, Ser, Asp, Glu, Gla, Gln, Gly, Val, Asp, Asn, Ala, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa6 is Thr, Ser, Asp, Asn, Met, Val, Ala, Gly, Leu, Ile, Phe, any unnatural aromatic amino acid, Pro, hydroxy-Pro, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa7 is Ile, Leu, Val, Ser, Thr, Gln, Asn, Asp, Arg, His, halo-His, Phe, any unnatural aromatic amino acid, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa8 is Pro, hydroxy-Pro, Ser, Thr, Ile, Asp, Leu, Val, Gly, Ala, Phe, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa9 is Val, Ala, Gly, Ile, Leu, Asp, Ser, Thr, Pro, hydroxy-Pro, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa10 is His, halo-His, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Asn, Ala, Ser, Thr, Phe, Ile, Leu, Gly, Trp (D or L), neo-Trp, halo-Trp, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa11 is Leu, Gln, Val, Ile, Gly, Met, Ala, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Ser, Thr, Arg, homoarginine, ornithine, any unnatural basic amino acid, Asn, Glu, Gla, Gln, Phe, Trp (D or L), neo-Trp, halo-Trp or any unnatural aromatic amino acid; Xaa12 is Glu, Gla, Gln, Asn, Asp, Pro, hydroxy-Pro, Ser, Gly, Thr, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, Arg, homoarginine, ornithine, any unnatural basic amino acid, Phe, His, halo-His, any unnatural aromatic amino acid, Leu, Met, Gly, Ala, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa13 is His, halo-His, Asn, Thr, Ser, Ile, Val, Leu, Phe, any unnatural aromatic amino acid, Arg, homoarginine, ornithine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Try, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa14 is Ser, Thr, Ala, Gln, Pro, hydroxy-Pro, Gly, Ile, Leu, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa15 is Asn, Glu, Gla, Asp, Gly, His, halo-His, Ala, Leu, Gln, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys, any unnatural basic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr or any unnatural hydroxy containing amino acid; Xaa16 is Met, Ile, Thr, Ser, Val, Leu, Pro, hydroxy-Pro, Phe, any unnatural aromatic amino acid, Tyr, nor-Tyr, mono-halo-Tyr, di-halo-Tyr, O-sulpho-Tyr, O-phospho-Tyr, nitro-Tyr, any unnatural hydroxy containing amino acid, Glu, Gla, Ala, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa17 is des-Xaa17, Gly, Asp, Asn, Ala, Ile, Leu, Ser, Thr, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa18 is des-Xaa18, Gly, Glu, Gla, Gln, Trp (D or L), neo, halo-Trp, any unnatural aromatic amino acid, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa19 is des-Xaa19, Ser, Thr, Val, Ile, Ala, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa20 is des-Xaa20, Val, Asp, His, halo-His, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa21 is des-Xaa21, Asn, Pro or hydroxy-Pro; Xaa22 is des-Xaa22, Arg, ornithine, homoarginine, Lys, N-methyl-Lys, N,N-dimethyl-Lys, N,N,N-trimethyl-Lys or any unnatural basic amino acid; Xaa23 is des-Xaa23, Ser or Thr; Xaa24 is des-Xaa24, Leu, Ile or Val; and the C-terminus contains a free carboxyl group or an amide group, with the proviso that (a) Xaa5 is not Gly, when Xaa1 is des-Xaa1, Xaa2 is des-Xaa2, Xaa3 is des-Xaa3, Xaa4 is des-Xaa4, Xaa6 is Ser, Xaa7 is His, Xaa8 is Pro, Xaa9 is Ala, Xaa10 is Ser, Xaa11 is Val, Xaa12 is Asn, Xaa13 is Asn, Xaa14 is Pro, Xaa15 is Asp, Xaa16 is Ile, Xaa17 is des-Xaa17, Xaa18 is des-Xaa18, Xaa19 is des-Xaa19, Xaa20 is des-Xaa20, Xaa21 is des-Xaa21, Xaa22 is des-Xaa22, Xaa23 is des-Xaa23, and Xaa24 is des-Xaa24.
  • 19. An isolated α-conotoxin peptide of the generic formula III (SEQ ID NO:3) of claim 18 selected from the group consisting of:
  • 20. The isolated α-conotoxin peptide of claim 19, wherein Xaa2 is Lys.
  • 21. The isolated α-conotoxin peptide of claim 19, wherein Xaa1 is Glu.
  • 22. The isolated α-conotoxin peptide of claim 19, wherein Xaa3 is Trp.
  • 23. The isolated α-conotoxin peptide of claim 19, wherein Xaa4 is Tyr.
  • 24. The isolated α-conotoxin peptide of claim 19, wherein Xaa4 is mono-iodo-Tyr.
  • 25. The isolated α-conotoxin peptide of claim 19, wherein Xaa4 is di-iodo-Tyr.
  • 26. The isolated α-conotoxin peptide of claim 18, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 27. The isolated α-conotoxin peptide of claim 19 which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 28. An isolated α-conotoxin peptide selected from the group consisting of:
  • 29. The isolated α-conotoxin peptide of claim 28, wherein Xaa2 is Lys.
  • 30. The isolated α-conotoxin peptide of claim 28, wherein Xaa1 is Glu.
  • 31. The isolated α-conotoxin peptide of claim 28, wherein Xaa4 is Tyr.
  • 32. The isolated α-conotoxin peptide of claim 28, wherein Xaa4 is mono-iodo-Tyr.
  • 33. The isolated α-conotoxin peptide of claim 28, wherein Xaa4 is di-iodo-Tyr.
  • 34. The isolated α-conotoxin peptide of claim 28, which is modified to contain an O-glycan, an S-glycan or an N-glycan.
  • 35. An isolated α-conotoxin protein precursor comprising an amino acid sequence selected from the group of amino acid sequences set forth in Tables 1-134.
CROSS-REFERENCE TO RELATED APPLICATION

The present application is a division of U.S. patent application Ser. No. 10/895,372 filed 21 Jul. 2004, now U.S. Pat. No. 7,279,549, which in turn is a division of U.S. patent application Ser. No. 09/493,795 filed 28 Jan. 2000, now U.S. Pat. No. 6,797,808. U.S. patent application Ser. No. 09/493,795 is related to and claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application Ser. No. 60/118,381, filed 29 Jan. 1999. Each application is incorporated herein by reference.

Government Interests

This invention was made with Government support under Grant No. PO1 GM48677 awarded by the National Institute of General Medical Sciences, National Institutes of Health, Bethesda, Md. The United States Government has certain rights in the invention.

Provisional Applications (1)
Number Date Country
60118381 Jan 1999 US
Divisions (2)
Number Date Country
Parent 10895372 Jul 2004 US
Child 11869480 Oct 2007 US
Parent 09493795 Jan 2000 US
Child 10895372 Jul 2004 US